<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding - Hayes, K - 2022 | Cochrane Library</title> <meta content="Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding - Hayes, K - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013551.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding - Hayes, K - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013551.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013551.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding" name="citation_title"/> <meta content="Katia Hayes" name="citation_author"/> <meta content="Auckland City Hospital" name="citation_author_institution"/> <meta content="khayes@adhb.govt.nz" name="citation_author_email"/> <meta content="Malindra C Fernando" name="citation_author"/> <meta content="Auckland City Hospital" name="citation_author_institution"/> <meta content="Vanessa Jordan" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013551.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/11/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013551.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013551.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013551.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Cardiac Surgical Procedures [adverse effects]; Erythrocyte Transfusion; *Hemorrhage [etiology, therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013551.pub2&amp;doi=10.1002/14651858.CD013551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="p32VIvbS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013551\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013551\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ko","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013551.pub2",title:"Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding",firstPublishedDate:"Nov 21, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013551.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013551.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013551.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013551.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013551.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013551.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013551.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013551.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013551.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013551.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2882 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013551.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-sec-0079"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/appendices#CD013551-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/supinfo/CD013551StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/supinfo/CD013551StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/information#CD013551-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Katia Hayes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/information#CD013551-cr-0005">Malindra C Fernando</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013551.pub2/information#CD013551-cr-0006">Vanessa Jordan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/information/en#CD013551-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 November 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013551.pub2">https://doi.org/10.1002/14651858.CD013551.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013551-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013551-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013551-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013551-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013551-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013551-abs-0004">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013551-abs-0001" lang="en"> <section id="CD013551-sec-0001"> <h3 class="title" id="CD013551-sec-0001">Background</h3> <p>Coagulopathy following cardiac surgery is associated with considerable blood product transfusion and high morbidity and mortality. The treatment of coagulopathy following cardiac surgery is challenging, with the replacement of clotting factors being based on transfusion of fresh frozen plasma (FFP). Prothrombin complex concentrate (PCCs) is an alternative method to replace clotting factors and warrants evaluation. PCCs are also an alternative method to treat refractory ongoing bleeding post‐cardiac surgery compared to recombinant factor VIIa (rFVIIa) and also warrants evaluation.   </p> </section> <section id="CD013551-sec-0002"> <h3 class="title" id="CD013551-sec-0002">Objectives</h3> <p>Assess the benefits and harms of PCCs in people undergoing cardiac surgery who have coagulopathic non‐surgical bleeding. </p> </section> <section id="CD013551-sec-0003"> <h3 class="title" id="CD013551-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, Embase and Conference Proceedings Citation Index‐Science (CPCI‐S) on the Web of Science on 20 April 2021. We searched Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), and the World Health Organisation (WHO) International Clinical Trials Registry Platform (ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>), for ongoing or unpublished trials. We checked the reference lists for additional references. We did not limit the searches by language or publication status. </p> </section> <section id="CD013551-sec-0004"> <h3 class="title" id="CD013551-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and non‐randomised trials (NRSs). </p> </section> <section id="CD013551-sec-0005"> <h3 class="title" id="CD013551-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.  </p> </section> <section id="CD013551-sec-0006"> <h3 class="title" id="CD013551-sec-0006">Main results</h3> <p>Eighteen studies were included  (4993 participants). Two were RCTs (151 participants) and 16 were NRSs. Both RCTs had low risk of bias (RoB) in almost all domains. Of the 16 NRSs, 14 were retrospective cohort analyses with one prospective study and one case report. The nine studies used in quantitative analysis were judged to have critical RoB, three serious and three moderate.   </p> <p><b>1. PCC versus standard treatment </b> </p> <p>Evidence from RCTs showed PCCs are likely to reduce the number of units transfused compared to standard care (MD ‐0.89, 95% CI ‐1.78 to 0.00; participants = 151; studies = 2; moderate‐quality evidence). Evidence from NRSs agreed with this, showing that PCCs may reduce the mean number of units transfused compared to standard care but the evidence is uncertain (MD ‐1.87 units, 95% CI ‐2.53 to ‐1.20; participants = 551; studies = 2; very low‐quality evidence). </p> <p>There was no evidence from RCTs showing a difference in the incidence of red blood cell (RBC) transfusion compared to standard care (OR 0.53, 95% CI 0.20 to 1.40; participants = 101; studies = 1; low‐quality evidence). Evidence from NRSs disagreed with this, showing that PCCs may reduce the mean number of units transfused compared to standard care but the evidence is uncertain (OR 0.54, 95% CI 0.30 to 0.98; participants = 1046; studies = 4; low‐quality evidence). </p> <p>There was no evidence from RCTs showing a difference in the number of thrombotic events with PCC compared to standard care (OR 0.68 95% CI 0.20 to 2.31; participants = 152; studies = 2; moderate‐quality evidence). This is supported by NRSs, showing that PCCs may have no effect on the number of thrombotic events compared to standard care but the evidence is very uncertain (OR 1.32, 95% CI 0.87 to 1.99; participants = 1359; studies = 7; very low‐quality evidence). </p> <p>There was no evidence from RCTs showing a difference in mortality with PCC compared to standard care  (OR 0.53, 95% CI 0.12 to 2.35; participants = 149; studies = 2; moderate‐quality evidence). This is supported by evidence from NRSs, showing that PCCs may have little to no effect on mortality compared to standard care but the evidence is very uncertain (OR 1.02, 95% CI 0.69 to 1.51; participants = 1334; studies = 6; very low‐quality evidence). </p> <p>Evidence from RCTs indicated that there was little to no difference in postoperative bleeding (MD ‐107.05 mLs, 95% CI ‐278.92 to 64.83; participants = 151, studies = 2; low‐quality evidence).  </p> <p>PCCs may have little to no effect on intensive care length of stay (RCT evidence: MD ‐0.35 hours, 95% CI ‐19.26 to 18.57; participants = 151; studies = 2; moderate‐quality evidence) (NRS evidence: MD ‐18.00, 95% CI ‐43.14 to 7.14; participants = 225; studies = 1; very low‐quality evidence) or incidence of renal replacement therapy (RCT evidence: OR 0.72, 95% CI 0.14 to 3.59; participants = 50; studies = 1; low‐quality evidence) (NRS evidence: OR 1.46, 95% CI 0.71 to 2.98; participants = 684; studies = 2; very low‐quality evidence). </p> <p>No studies reported on additional adverse outcomes.  </p> <p><b>2. PCC versus rFVIIa </b> </p> <p>For this comparison, all evidence was provided from NRSs. </p> <p>PCC likely results in a large reduction of RBCs transfused intra‐operatively in comparison to rFVIIa (MD‐4.98 units, 95% CI ‐6.37 to ‐3.59; participants = 256; studies = 2; moderate‐quality evidence).  </p> <p>PCC may have little to no effect on the incidence of RBC units transfused comparative to rFVIIa; evidence is very uncertain (OR 0.16, 95% CI 0.02 to 1.56; participants = 150; studies = 1; very low‐quality evidence). </p> <p>PCC may have little to no effect on the number of thrombotic events comparative to rFVIIa; evidence is very uncertain (OR 0.51, 95% CI 0.23 to 1.16; participants = 407; studies = 4; very low‐quality evidence). </p> <p>PCC may have little to no effect on the incidence of mortality (OR 1.07, 95% CI 0.38 to 3.03; participants = 278; studies = 3; very low‐quality evidence) or intensive care length of stay comparative to rFVIIa (MD ‐40 hours, 95% CI ‐110.41 to 30.41; participants = 106; studies = 1; very low‐quality evidence); evidence is very uncertain . </p> <p>PCC may reduce bleeding (MD ‐674.34 mLs, 95% CI ‐906.04 to ‐442.64; participants = 150; studies = 1; very low‐quality evidence) and incidence of renal replacement therapy (OR 0.29, 95% CI 0.12 to 0.71; participants = 106; studies = 1; very low‐quality evidence) comparative to rFVIIa; evidence is very uncertain. </p> <p>No studies reported on other adverse events. </p> </section> <section id="CD013551-sec-0007"> <h3 class="title" id="CD013551-sec-0007">Authors' conclusions</h3> <p>PCCs could potentially be used as an alternative to standard therapy for coagulopathic bleeding post‐cardiac surgery compared to FFP as shown by moderate‐quality evidence and it may be an alternative to rFVIIa in refractory non‐surgical bleeding but this is based on moderate to very low quality of evidence.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013551-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013551-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013551-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013551-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013551-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013551-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013551-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013551-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013551-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013551-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013551-abs-0002" lang="en"> <h3>Prothrombin complex concentrate in the treatment of bleeding that occurs with heart surgery </h3> <p>This purpose of this review was to assess the current evidence on whether prothrombin complex concentrates are safe to use to prevent bleeding following heart surgery. We also assessed its ability to reduce death and other serious complications when compared to other therapies.  </p> <p><b>Background</b> </p> <p>Bleeding following complex heart surgery can be challenging to manage. The blood clotting pathway is complex, and when the patient is placed on the heart bypass machine, there is a reduction of certain components from blood. Clotting factors can be significantly reduced depending on the duration of bypass. Fresh frozen plasma and prothrombin complex concentrates are the only recognised methods of replacing these clotting factors. Fresh frozen plasma is presented in 250 to 300 mL volume bags which can increase the total blood volume but may place extra strain on the heart. Prothrombin complex concentrates are presented in a powder that is reconstituted and delivered in a smaller volume. This product works faster as the factors are concentrated and given quickly compared to the slow infusion of dilute fresh frozen plasma. Recombinant factor VIIa (rFVIIa) is another blood clotting factor made in the lab, but not from humans. It is used when the bleeding is so bad than no blood products can fix it. We compared how effective prothrombin complex concentrates are to rFVIIa. </p> <p><b>Study characteristics</b> </p> <p>The evidence is up‐to‐date to 20 April 2021. We included 18 studies with a total of 4993 participants who were undergoing heart surgery. From these 18 studies, two were pilot randomised control trials (RCTs) and 16 were non randomised studies (NRSs). Thirteen of these NRS studies were in adults and three were in children. The two types of prothrombin complex concentrates used were 3‐factor (contains three clotting factors) and 4‐factor (contains four clotting factors). These prothrombin complex concentrates were compared to standard therapy in eleven studies and rFVIIa in five studies, with the remaining two studies having no comparator. </p> <p>The clotting products were given in the operating room in nine studies, intensive care and operating room in three studies and were not described in the remaining six studies. We excluded any study that used the clotting products to reverse the actions caused by blood thinning medications that the patient was already taking.  </p> <p><b>Key results</b> </p> <p><i>Prothrombin complex concentrates compared to standard therapy</i> </p> <p>Prothrombin complex concentrates had an overall reduction in red blood cell (RBC) transfusion (both units of RBC transfusion and incidence of RBC transfusion) when compared to fresh frozen plasma. There was potentially no reduction in chest drain output (bleeding) in the RCTs. There was no difference in the reported outcomes of blood clots, death, intensive care stay and the requirement of dialysis in both RCTs and NRSs. The RCTs had moderate to low quality of evidence and the NRS had very low to low quality of evidence.  </p> <p><i>Prothrombin complex concentrates compared to</i> rFVIIa  </p> <p>Prothrombin complex concentrates had a large reduction in red blood cell transfusion when compared to rFVIIa. The quality of this evidence was moderate. For the remaining outcomes that we reviewed, there were only two studies that could be analysed. These studies found that there was no difference in blood clots, death, bleeding into drains, intensive care stay and the requirement for dialysis. This lack of difference could result from the lack of ability of low participant numbers to find these rarer outcomes. The quality of the evidence for these outcomes was very low.  </p> <p><b>Quality of evidence</b> </p> <p>The RCTs had a low risk of bias, but the overall quality of the evidence was graded as moderate for the majority of outcomes, rather than high due to low sample numbers. For the remaining outcomes, the evidence was graded as low as there was only one RCT that contributed to those outcomes.   </p> <p>The quality of evidence for the NRSs was low to very low. Many of the retrospective studies had significant confounding that may have influenced the final outcome.   </p> <p><b>Conclusion</b> </p> <p>Prothrombin complex concentrates may reduce RBC transfusion rates (both the quantity of RBC transfusion and the incidence of RBC transfusion) in patients with bleeding issues following heart surgery when compared with standard care. We didn't identify a difference in any of the other outcomes but the total number of participants in the studies was likely insufficient to detect an outcome difference.  </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013551-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013551-sec-0092"></div> <h3 class="title" id="CD013551-sec-0093">Implications for practice</h3> <section id="CD013551-sec-0093"> <section id="CD013551-sec-0094"> <h5 class="title">PCCs versus standard treatment (FFP)</h5> <p>This review has found that PCCs could be used as an alternative to standard therapy for coagulopathic bleeding post‐cardiac surgery with moderate quality of evidence from RCTs which is in agreement with low‐quality evidence NRSs. There is a reduction in RBC transfusion and there may be a reduction in the incidence of RBC transfusion when PCCs are used as factor replacement in coagulopathic bleeding.  </p> <p>There is uncertainty around the optimal but safe dosing of PCCs. Adult doses in the included studies ranged from 12 units/kg to 28 units/kg. Some studies only reported a total dose, which ranged from 545 units to a maximum dose of 2000 to 3000 units, but without the weight range, the doses could not be compared.  </p> <p>In the three paediatric studies, doses ranged from 25 units/kg to 57 units/kg. Further analysis was unable to be performed due to the lack of paediatric studies. The paediatric studies all underwent high‐risk complex congenital surgery and are highly representative of the paediatric cardiac surgical population but, despite the high doses, did not show an increased risk of thrombosis.   </p> <p>There is a theoretical risk of increased thrombosis with 3‐factor PCC due to a lack of protein C and S. Our subgroup analysis looking at 3‐factor versus 4‐factor PCC showed there was no difference in the thrombotic events between these two types.  </p> </section> <section id="CD013551-sec-0095"> <h5 class="title">PCCs versus rFVIIa</h5> <p>PCCs may result in a large reduction in the number of RBCs transfused with moderate quality of evidence in refractory coagulopathic bleeding post‐cardiac surgery, but we are unsure of their effects on all other outcomes because the quality of evidence was very low.   </p> </section> </section> <h3 class="title" id="CD013551-sec-0096">Implications for research</h3> <section id="CD013551-sec-0096"> <p>The current research published are two pilot RCTs and 16 NRSs. To increase the certainty of these conclusions, we propose that well‐constructed and powered multicentred trials would be required. These studies should use a well‐defined bleeding algorithm, set an appropriate dose of PCCs and its comparator, and study only the high‐risk cardiac surgical population. We also propose that future research clearly define outcomes such as thrombosis and how it was diagnosed. </p> <p>A standardised PCC dose and FFP dose of equal factor replacement should be given and compared in future studies. An acceptable initial dose of PCCs is 10 to 20 units/kg. An equal dose of FFP for factor replacement is about 10‐20 mL/kg. This is general guidance based on equivalent doses of factor IX in each of the products, however, it must be noted that levels of factors in donor plasma will differ. </p> <p>A standardised coagulation algorithm should also be used within institutions with the use of point‐of‐care viscoelastic testing. This ensures that a logical stepwise process in treating coagulopathy is completed, addressing  deficiencies in protamine post‐bypass, followed by replacement of fibrinogen and platelets and finally, if point‐of‐care testing shows a factor deficiency, PCCs are given.  </p> <p>The second type of use of PCCs is in refractory coagulopathic bleeding instead of rFVIIa. This is where all coagulation constituents are optimised with adequate fibrinogen, platelet, coagulation factors and normalised physiological parameters, however, there is ongoing diffuse microvascular bleeding. Historically, rFVIIa has been used in this situation. Future studies need to ensure that the basics of coagulation are optimised first with a logical algorithm followed and PCCs only used in refractory bleeding.   </p> <p>We believe there is little benefit of PCCs in the low‐risk cardiac surgical population as these patients rarely become factor deficient and can tolerate the volume of FFP. Risk factors for developing factor deficiency during cardiac surgery include prolonged CPB time, low target temperature on bypass (hypothermia impairing liver production of coagulation factors), and foreign graft material such as aortic replacements.  Higher‐risk patients often can not tolerate large volume transfusions of FFP due to poor right heart function or lung disease. These are the patients most likely to benefit from PCCs and should be studied in future. We are aware that some countries do not have access to FFP and all their factor replacement transfusions are done with PCCs alone. This study is therefore only relevant to countries that still use FFP as standard therapy in cardiac surgery.   </p> <p>Outcome measures should look at the incidence of acute renal impairment with a standardised internationally recognised acute kidney injury score such as the AKIN criteria. There is uncertainty whether PCCs may be causing renal microemboli causing acute kidney injury or via another unknown mechanism. There is also uncertainty whether the large volumes of FFP required for factor replacement is causing interstitial oedema within the kidneys and impairing glomerular blood flow and therefore contributing to acute kidney injury. We only looked at incidence of renal replacement therapy due to the varied and lack of consistent ways in which studies reported on kidney injury.   </p> <p>Only one study prospectively screened for embolic events with daily echocardiography and daily ultrasound (USS) of the legs. We can only assume that most studies made a clinical diagnosis of stroke or DVT and did not actively screen for them. This may be the most clinically relevant way to report on thromboembolic events, however, in future research, this should be prospectively screened for as clinical notes can miss important events.   </p> <p>Both moderate and low‐quality evidence suggests there is a benefit of PCCs in the cardiac surgical population, which justifies undertaking future high‐quality trials to confirm the place of PCCs.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013551-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013551-sec-0008"></div> <div class="table" id="CD013551-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">PCC compared to standard treatment for cardiac surgery for the treatment of non‐surgical bleeding</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PCC compared to standard treatment for cardiac surgery for the treatment of non‐surgical bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> cardiac surgery for the treatment of non‐surgical bleeding<br/><b>Setting:</b> hospital (intraoperative and postoperative)<br/><b>Intervention:</b> PCC<br/><b>Comparison:</b> standard treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PCC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood products transfused (RBC) in units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean RCT: Blood products transfused (RBC) in units was 3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p>0.89 lower</p> <p>(1.78 lower to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two pilot RCTs <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>; reported blood components in units at 24 hours and <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> reported units within 24 hours of start of surgery.   </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean NRS: blood products transfused (RBC) in units was 5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 1.87 lower<br/>(2.53 lower to 1.20 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>551<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two observational studies described intraoperative red cell transfusion (<a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>). They described this in mLs of red cells transfused and converted to units by assuming an average of 250 mL of blood per unit. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Blood products transfused (RBC) % of patients</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>830 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>721 per 1000<br/>(494 to 872) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.53<br/>(0.20 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One RCT <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> reported on incidence of RBC transfusion. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>889 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>812 per 1000<br/>(706 to 887) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.54<br/>(0.30 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1046<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three observational studies described the incidence of a red cell transfusion (<a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>). <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> reported avoidance of red cell transfusion. <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> had a greater number of the PCC group receiving red cell transfusion but this was not significant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Thrombotic events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>95 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>64 per 1000<br/>(20 to 194) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.68<br/>(0.20 to 2.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two pilot RCTs. <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> reported on many thrombotic events; we only included those of stroke as the other outcomes e.g. mesenteric artery thrombosis and spinal cord ischaemia are more likely related to other complex factors. <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> reported on stroke/TIA, atrial and vascular thrombosis.  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>68 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000<br/>(60 to 126) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.32<br/>(0.87 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1359<br/>(7 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a> reported on acute cerebral infarcts only. <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> reported on postoperative myocardial infarction and cerebral infarcts. <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> reported on cerebral infarcts and venous thromboembolism (deep vein thrombosis and pulmonary embolism). <a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a> and <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> did not define how they measured thrombosis. <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> measured both arterial and venous thrombosis. One study (<a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>) reported 0 events for both PCC and standard care groups and therefore did not contribute to the meta‐analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Mortality (30‐day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>39 per 1000<br/>(9 to 151) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.53 (0.12 to 2.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two pilot RCTs reported on this (<a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>; <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>); lost 4 to follow‐up at 30 days.  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>83 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000<br/>(59 to 120) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.02<br/>(0.69 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1334<br/>(6 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup><sup>3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a>; <a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> described 30‐day mortality. <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> reported on in‐hospital mortality with no time frame given. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Intensive care length of stay in hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean RCT intensive care length of stay in hours was 84</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD</p> <p>0.35 lower</p> <p>(19.26 lower to 18.57 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two pilot RCTs with <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> reporting on ICU or HDU stay in days and <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> median ICU stay in days.   </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean NRS intensive care length of stay in hours was 128</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 18.00 lower<br/>(43.14 lower to 7.14 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>450<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3  5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> reported on ICU length of stay with a mean of 110 hours (+/‐ 118) in the PCC group and a mean of 128 hours (+/‐ 152) in the standard treatment group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of renal impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>120 per 1000<br/>(30 to 482) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.72 (0.14 to 3.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One pilot RCT (<a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>) reported on number of patients requiring haemodialysis. <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> combined both haemodialysis and acute kidney injury with a 2‐fold increase in creatinine.   </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>41 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/>(29 to 113) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.46<br/>(0.71 to 2.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>684<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> and <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> reported on renal impairment postoperatively. Overall incidence was low with 20 patients in the PCC group and 14 in the standard treatment group. <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> used the RIFLE criteria to define acute kidney injury. <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> used serum creatinine measured from before surgery to the highest creatinine concentration on postoperative days 1 or 2. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding (chest drain output) in mLs for the first 12 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean RCT: Bleeding (chest drain output) in mLs for the first 12 hours was</p> <p>552</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD</p> <p>107.05 lower</p> <p>(278.92 lower to 64.83 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for imprecision as number of participants &lt; 400 </p> <p><sup>2</sup>Downgraded two levels for risk of bias associated with lack of randomisation </p> <p><sup>3</sup>Downgraded one level for risk of bias </p> <p><sup>4</sup>Downgraded one level for imprecision as number of events were &lt; 400 </p> <p><sup>5</sup>Downgraded one level for indirectness as only one study which did not represent all potential participants </p> <p><sup>6</sup>Downgraded one level for inconsistency </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013551-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">PCC compared to FVIIa for cardiac surgery for the treatment of non‐surgical bleeding</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PCC compared to FVIIa for cardiac surgery for the treatment of non‐surgical bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> cardiac surgery for the treatment of non‐surgical bleeding<br/><b>Setting:</b> hospital (intraoperative and postoperative)<br/><b>Intervention:</b> PCC<br/><b>Comparison:</b> FVIIa </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with FVIIa</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PCC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood products transfused (RBC) in units ‐ intraoperative</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood products transfused (RBC) in units ‐ intraoperative was 12</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.98 lower<br/>(6.37 lower to 3.59 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 2 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> and <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> reported on intraoperative red cell transfusion. <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> used mLs of red cells transfused and we converted to units by assuming 250 mL per unit of red cells. Overall effect was clinically significant with a 5 unit of red cells difference in the PCC group. However, in both <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> and <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>, the rFVIIa group may include higher risk cardiac surgical patients. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood products transfused (RBC) % of patients</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>990 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>941 per 1000<br/>(664 to 994) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.16<br/>(0.02 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2  5 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> reported on incidence of red cell transfusion in patients. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombotic events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/>(22 to 103) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.51<br/>(0.23 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>407<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three studies reported on incidence of postoperative thrombosis; <a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a>; <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>; <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>. <a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a> reported this as all thromboembolic events but this was not defined. <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> defined thromboembolism as new cerebral vascular events, deep vein thrombosis, pulmonary embolism, myocardial infarction or new intracardiac thrombus. In <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>, thromboembolic events defined as venous thromboembolism, arterial thromboembolism or pulmonary embolism that occurred at any time postoperatively.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (30‐day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>135 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000<br/>(56 to 320) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.07<br/>(0.38 to 3.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> and <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> reported on 30‐day mortality. <a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a> reported on in‐hospital mortality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding (chest drain output) in mLs for the first 12 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean bleeding (chest drain output) in mLs for the first 12 hours was 1398</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 674.34 lower<br/>(906.04 lower to 442.64 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> was the only study that reported on 12‐hour chest drain output with a mean of 723.33 mL (+/‐ 442.78) in the PCC group and mean of 1397.67 mL (+/‐ 1002.69) in the rFVIIa group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive care length of stay in hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean intensive care length of stay in hours was 196</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 40 lower<br/>(110.41 lower to 30.41 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> was the only study that reported on ICU length of stay with a mean of 156 hours (+/‐ 155.46) in the PCC group and a mean of 196 hours (+/‐ 210.32) in the rFVIIa group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incidence of renal impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>415 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000<br/>(78 to 335) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.29<br/>(0.12 to 0.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 5 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> reported on new acute kidney injury by the incidence of patients requiring postoperative dialysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels for risk of bias associated with lack of randomisation  </p> <p><sup>2</sup>Downgraded one level for risk of bias </p> <p><sup>3</sup>Downgraded one level for precision as number of participants &lt; 400 </p> <p><sup>4</sup>Upgraded two levels due to very large effect size </p> <p><sup>5</sup>Downgraded one level for precision as number of events were &lt; 400 </p> <p><sup>6</sup>Downgraded one level for indirectness as only one study which did not represent all potential participants </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013551-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013551-sec-0009"></div> <section id="CD013551-sec-0010"> <h3 class="title" id="CD013551-sec-0010">Description of the condition</h3> <p>Cardiac surgery is known to be associated with high blood product transfusion requirements and, in turn, allogeneic blood transfusion is associated with higher rates of morbidity and mortality (<a href="./references#CD013551-bbs2-0055" title="Arias-MoralesCE , StoiceaN , Gonzalez-ZacariasAA , SlawskiD , BhandarySP , SaranteasT , et al. Revisiting blood transfusion and predictors of outcome in cardiac surgery patients: a concise perspective. F1000Research2017;6:168-75. [DOI: 10.12688/f1000research.10085.1. eCollection 2017]">Arias‐Morales 2017</a>; <a href="./references#CD013551-bbs2-0083" title="KilicA , WhitmanGJ . Blood transfusions in cardiac surgery: indications, risks, and conservation strategies. Annals of Thoracic Surgery2014;97(2):726-34.">Kilic 2014</a>). In 2016, it was estimated that one million people throughout the world undergo cardiac surgery each year (<a href="./references#CD013551-bbs2-0110" title="VeluzJS , LearyMC . Cerebrovascular complications of cardiac surgery. In: Primer on Cerebrovascular Diseases. 2nd edition. Elsevier, 2017:650-5.">Veluz 2017</a>). This number is only likely to increase with our ageing population. In the UK, there are 30,000 cardiac procedures performed each year and it is estimated that 30% of these require plasma transfusion for bleeding and management of coagulopathy (<a href="./references#CD013551-bbs2-0058" title="BortolussiG , McNultyD , WaheedH , MawhinneyJA , FreemantleN , PaganoD . Identifying cardiac surgery operations in hospital episode statistics administrative database, with an OPCS-based classification of procedures, validated against clinical data. BMJ Open2019;9(3):e023316.">Bortolussi 2019</a>; <a href="./references#CD013551-bbs2-0073" title="GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684.">Green 2019</a>). </p> <p>There is considerable risk of postoperative bleeding due to contact activation within the extracorporeal circulation system, factor degradation, platelet dysfunction and activation, fibrinogen consumption, reduced liver production of factors, foreign graft material, multiple suture lines, and raw open vascular surfaces (<a href="./references#CD013551-bbs2-0054" title="AchneckHE , SileshiB , ParikhA , MilanoCA , WelsbyIJ , LawsonJH . Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. Circulation2010;122(20):2068-77.">Achneck 2010</a>). </p> <p>Platelets may become activated but injury to these platelets may occur due to the shear forces of the cardiopulmonary bypass circuit and pump leading to impaired function. At the surgical site, blood is exposed to air and tissue factor, further activating the coagulation cascade. These processes will ultimately result in consumption of coagulation factors, platelets, and fibrinogen, as well as increased fibrinolysis (<a href="./references#CD013551-bbs2-0090" title="O'Carroll-KuehnBU , MeeranH . Management of coagulation during cardiopulmonary bypass. Continuing Education in Anaesthesia, Critical Care and Pain2007;7(6):195-8.">O'Carroll‐Kuehn 2007</a>). A non‐systematic search and review of the coagulation changes post‐cardiopulmonary bypass showed that plasma fibrinogen concentration decreases during cardiopulmonary bypass with a median reduction of 36% with platelet count decreasing by 44% (<a href="./references#CD013551-bbs2-0080" title="HöferJ , FriesD , SolomonC , Velik-SalchnerC , AussererJ . A snapshot of coagulopathy after cardiopulmonary bypass. Clinical and Applied Thrombosis/Hemostasis2016;22(6):505-11.">Höfer 2016</a>). They also showed that coagulation factors had an overall decrease in activity during cardiopulmonary bypass with factors II, V, VII, X, XI, and XIII all strongly decreased by an average of 47.0%, 39.9%, 23.5%, 40.3%, 35.6%, and 33.6%, respectively (<a href="./references#CD013551-bbs2-0080" title="HöferJ , FriesD , SolomonC , Velik-SalchnerC , AussererJ . A snapshot of coagulopathy after cardiopulmonary bypass. Clinical and Applied Thrombosis/Hemostasis2016;22(6):505-11.">Höfer 2016</a>). An animal study looking at swine, showed that, following cardiopulmonary bypass for two hours at 25 degrees Celsius, there was a fall of coagulation factors II, VII, IX and X up to 48% (<a href="./references#CD013551-bbs2-0082" title="KaspereitF , HoffmannS , PragstI , DickneiteG . Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model. British Journal of Anaesthesia2010;105(5):576-82.">Kaspereit 2010</a>). It is hypothesised that these factors exponentially decrease the longer the patient is on cardiopulmonary bypass and the lower the temperature. </p> </section> <section id="CD013551-sec-0011"> <h3 class="title" id="CD013551-sec-0011">Description of the intervention</h3> <p>Prothrombin complex concentrate (PCC) is fractionated and includes both 4‐factor concentrates (coagulation factors II, VII, IX, X) and 3‐factor concentrates (coagulation factors II, IX, X). In Europe and Canada, 4‐factor concentrates are predominantly used, for example, Beriplex and Octaplex (Octapharma), whereas in Australia and New Zealand the only preparation available is the 3‐factor concentrate e.g. Prothrombinex (CSL Behring) (<a href="./references#CD013551-bbs2-0105" title="SørensenB , SpahnDR , InnerhoferP , SpannaglM , RossaintR . Clinical review: prothrombin complex concentrates - evaluation of safety and thrombogenicity. Critical Care2011;15(1):201.">Sørensen 2011</a>). </p> <p>In the UK, factor concentrates became popular for treatment of haemophilia in the 1990s due to infectious risks associated with fresh frozen plasma (FFP) and cryoprecipitate (<a href="./references#CD013551-bbs2-0084" title="KöhlerM . Thrombogenicity of prothrombin complex concentrates. Thrombosis Research1999;95(4 Suppl 1):S13-7.">Köhler 1999</a>). On a global scale, in 2017, the EACTS/EACTA (European Association for Cardio‐Thoracic Surgery/European Association of Cardiothoracic Anaesthesiology) taskforce published a comprehensive patient blood management guideline. The authors have recommended the use of PCC for coagulation factor deficiency in the treatment of microvascular bleeding but do not give a recommended dose or timing (<a href="./references#CD013551-bbs2-0094" title="PaganoD , MilojevicM , MeestersMI , BenedettoU , BolligerD , HeymannC , et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery: the task force on patient blood management for adult cardiac surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiology. European Journal of Cardio-thoracic Surgery2018;53(1):79-111.">Pagano 2018</a>). Following on from this, in 2019, the American Society of Cardiovascular Anaesthesiologists have now included the use of low‐dose PCC in their perioperative blood management guideline as an alternative to FFP; however, this treatment is recommended with caution as there is still uncertainty about dosing and side effects (<a href="./references#CD013551-bbs2-0096" title="RaphaelJ , MazerCD , SubramaniS , SchroederA , AbdallaM , FerreiraR , et al. Society of Cardiovascular Anesthesiologists clinical practice improvement advisory for management of perioperative bleeding and hemostasis in cardiac surgery patients. Journal of Cardiothoracic and Vascular Anesthesia2019;33(11):2887-99.">Raphael 2019</a>). </p> <p>PCC comes with a potential prothrombic risk, given it is a low‐volume, high‐concentration of coagulation factors infused directly into the systemic circulation (<a href="./references#CD013551-bbs2-0103" title="SongHK , TibayanFA , KahlEA , SeraVA , SlaterMS , DelougheryTG , et al. Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. Journal of Thoracic and Cardiovascular Surgery2014;147(3):1036-40.">Song 2014</a>). Three‐factor concentrates do not have protein S and C, therefore, they can add to the potential risk of thrombosis. Thrombosis has been described as cerebrovascular events, myocardial infarction, pulmonary embolism and deep vein thrombosis (<a href="./references#CD013551-bbs2-0070" title="FranchiniM , LippiG . Prothrombin complex concentrates: an update. Blood Transfusion2010;8(3):149-54.">Franchini 2010</a>). In patients with a prior history of venous thromboembolism given 3‐factor PCC for reversal of warfarin in the setting of intracerebral haemorrhage, there was a 4.5 times increased risk of developing a venous thromboembolism within 30 days (<a href="./references#CD013551-bbs2-0068" title="FeltonD , FoleyEM , TraubSJ , VodonosA , GanetskyM . Risk of venous thromboembolism after receiving prothrombin complex concentrate for warfarin-associated intracranial hemorrhage. Journal of Emergency Medicine2016;50(1):1-6.">Felton 2016</a>). There has been one documented case study of massive thrombosis following PCC administration, of the superior vena cava to the pulmonary artery requiring reinstitution of cardiopulmonary bypass and thrombectomy (<a href="./references#CD013551-bbs2-0085" title="KosterA , Meyer-JarkT , SchirmerU , SandicaE . Fulminant intraoperative right heart and pulmonary artery thrombosis following prothrombin complex concentrate infusion after complex open heart surgery with cardiopulmonary bypass. A &amp; A Case Reports2014;2(8):89-91.">Koster 2014</a>). </p> <p>The true risk of acute kidney injury with PCC is unknown. Cappabiancca and colleagues showed an increased risk incidence of acute kidney injury and dialysis with PCC when compared to FFP (<a href="./references#CD013551-bbs2-0060" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care 2016 Jan 6 [Epub ahead of print];20(5):5. [DOI: 10.1186/s13054-015-1172-6]">Cappabianca 2016</a>). Subsequently, contrasting studies showed no increased risk of acute kidney injury (<a href="./references#CD013551-bbs2-0069" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34.">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0075" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia2018;32(1):151-7.">Harper 2018</a>). Further unknowns include the use of PCC for bleeding in patients with mechanical support such as left ventricular assist devices and extracorporeal membrane oxygenation. </p> <p>PCC has a low transfusion volume (a 500‐unit vial is reconstituted in 20 mL). The patient receives less overall fluid volume, which will potentially avoid volume overload of the right ventricle and reduce incidence of lung oedema. PCC is also not associated with transfusion‐related acute lung injury (TRALI). The advised rate of transfusion is 3 mL to 6 mL per minute or as tolerated by the patient (<a href="./references#CD013551-bbs2-0056" title="CS Behring. Product Information - Prothrombinex-VF. www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/prothrombinexvf-au-pi-1300.pdf?la=en-us&amp;hash=BC1625CF859B45E164CA759E7B871216243CFFBE (date accessed 16 December 2019).">Behring</a>; <a href="./references#CD013551-bbs2-0093" title="PabingerI , TiedeA , KalinaU , KnaubS , GermannR , OstermannH . Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. Annals of Hematology2010;89(3):309-16.">Pabinger 2010</a>). PCC has a shelf life of six months at room temperature and will allow for immediate availability for factor replacement. Unlike other clotting factors, PCC does not require blood group specificity and has an improved safety profile (<a href="./references#CD013551-bbs2-0106" title="TanakaKA , SzlamF . Treatment of massive bleeding with prothrombin complex concentrate: argument for. Journal of Thrombosis and Haemostasis2010;8(12):2589-91.">Tanaka 2010</a>). </p> <p>PCC is a sterile freeze‐powder containing purified human coagulation factors. The concentrate is produced by ion‐exchange chromatography from the cryoprecipitate of large plasma pools after removal of factor IX and antithrombin (<a href="./references#CD013551-bbs2-0070" title="FranchiniM , LippiG . Prothrombin complex concentrates: an update. Blood Transfusion2010;8(3):149-54.">Franchini 2010</a>). </p> <p> <ul id="CD013551-list-0001"> <li> <p>The 3‐factor PCC (e.g. Prothrombinex‐VF) is presented in 500 IU vials that contain 500 IU of factors II, IX and X, 25 IU of antithrombin 3, 192 IU of heparin and electrolyte buffers. </p> </li> <li> <p>The 4‐factor PCC (e.g. Beriplex) is presented in 500 IU vials that contain 380 to 800 IU of factor II, 200 to 500 IU of factor VII, 500 IU of factor IX, 500 to 1020 IU of factor X, 420 to 820 IU of protein C and 240 to 680 IU of protein S. </p> </li> </ul> </p> <p>Intravenous administration means that the preparation is available immediately, and bioavailability is 100%. Patients who received a 50 IU/kg intravenous dose, showed that peak plasma concentrations of the coagulation factors occur within five minutes of infusion (<a href="./references#CD013551-bbs2-0092" title="OstermannH , HaertelS , KnaubS , KalinaU , JungK , PabingerI . Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thrombosis and Haemostasis2007;98(4):790-7.">Ostermann 2007</a>). </p> <p>PCC is distributed and metabolised in the same way as endogenous coagulation factors (<a href="./references#CD013551-bbs2-0070" title="FranchiniM , LippiG . Prothrombin complex concentrates: an update. Blood Transfusion2010;8(3):149-54.">Franchini 2010</a>). </p> <p>PCC administration is contraindicated in patients with known allergy to heparin or history of heparin‐induced thrombocytopenia and with active thrombosis or disseminated intravascular coagulopathy. Heparin‐induced thrombocytopenia is related to the low level of porcine heparin in some types of PCCs e.g. Prothrombinex. There were no documented heparin‐induced thrombocytopenias secondary to PCCs in a pharmacovigilance study of Beriplex from 1996 to 2012 (<a href="./references#CD013551-bbs2-0074" title="HankeAA , JochC , GorlingerK . Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. British Journal of Anaesthesia2013;110(5):764-72.">Hanke 2013</a>). There are no known drug interactions with PCCs. </p> <p>Elimination half‐life of the coagulation factors is: factor II, 60 hours; factor VII, 4.2 hours; factor IX, 17 hours; and factor X, 31 hours (<a href="./references#CD013551-bbs2-0070" title="FranchiniM , LippiG . Prothrombin complex concentrates: an update. Blood Transfusion2010;8(3):149-54.">Franchini 2010</a>). </p> </section> <section id="CD013551-sec-0012"> <h3 class="title" id="CD013551-sec-0012">How the intervention might work</h3> <p>The treatment of bleeding diathesis following cardiac surgery is a considerable challenge and has been traditionally based on transfusion of allogeneic blood products (<a href="./references#CD013551-bbs2-0083" title="KilicA , WhitmanGJ . Blood transfusions in cardiac surgery: indications, risks, and conservation strategies. Annals of Thoracic Surgery2014;97(2):726-34.">Kilic 2014</a>). Typically, a volume of 20 mL/kg of FFP is required to produce a 30% increase in factor levels with a subsequent risk of transfusion‐associated fluid overload (TACO) (<a href="./references#CD013551-bbs2-0087" title="NascimentoB , CallumJ , RubenfeldG , NetoJR , LinY , RizoliS . Clinical review: fresh frozen plasma in massive bleedings - more questions than answers. Critical Care2010;14(1):202.">Nascimento 2010</a>). Substantial volumes of FFP are required to ensure adequate factor replacement and, as a consequence, there can be dilution of other clotting constituents, including platelets, fibrinogen and red blood cells (<a href="./references#CD013551-bbs2-0081" title="IshikuraH , KitamuraT . Trauma-induced coagulopathy and critical bleeding: the role of plasma and platelet transfusion. Journal of Intensive Care2017;5(2):1-8.">Ishikura 2017</a>; <a href="./references#CD013551-bbs2-0087" title="NascimentoB , CallumJ , RubenfeldG , NetoJR , LinY , RizoliS . Clinical review: fresh frozen plasma in massive bleedings - more questions than answers. Critical Care2010;14(1):202.">Nascimento 2010</a>). PCC is currently used in the treatment and perioperative prophylaxis of acquired deficiency of prothrombin complex factors and bleeding in patients with congenital deficiency of individual coagulation factors when specific products are not available (<a href="./references#CD013551-bbs2-0066" title="EstradaVH , FrancoDL , MorenoAA , GambasicaJA , NunezCC . Postoperative right ventricular failure in cardiac surgery. Cardiology Research2016;7(6):185-95.">Estrada 2016</a>; <a href="./references#CD013551-bbs2-0102" title="SiddonAJ , TormeyCA . Successful use of four factor-prothrombin complex concentrate for congenital factor X deficiency in the setting of neurosurgery. Laboratory Medicine2016;47(3):e35-7.">Siddon 2016</a>; <a href="./references#CD013551-bbs2-0109" title="Van VeenJJ , HamptonKK , MacleanR , FairlieF , MakrisM . Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy. Blood Transfusion2007;5(4):204-9.">Van Veen 2007</a>). It is also used in the treatment of warfarin reversal prior to urgent or emergency surgery (<a href="./references#CD013551-bbs2-0057" title="BordeleauS , PoitrasJ , MarceauD , BretonC , BeaupreP , ArchambaultPM . Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays. BMC Health Services Research 2015 Mar 15 [Epub ahead of print];15:106. [DOI: 10.1186/s12913-015-0775-6]">Bordeleau 2015</a>; <a href="./references#CD013551-bbs2-0107" title="UnoldD , TormeyCA . Clinical applications of 4-factor prothrombin complex concentrate: a practical pathologist's perspective. Archives of Pathology and Laboratory Medicine2015;139(12):1568-75.">Unold 2015</a>; <a href="./references#CD013551-bbs2-0109" title="Van VeenJJ , HamptonKK , MacleanR , FairlieF , MakrisM . Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy. Blood Transfusion2007;5(4):204-9.">Van Veen 2007</a>). Studies of PCC for warfarin reversal show that there is reversal of anticoagulation within 10 minutes following administration (<a href="./references#CD013551-bbs2-0098" title="RiessHB , Meier-HellmannA , MotschJ , EliasM , KurstenFW , DempfleCE . Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thrombosis Research2007;121(1):9-16.">Riess 2007</a>), in comparison to FFP, which takes hours, and with which INR (International Normalised Ratio) correction can also be incomplete (<a href="./references#CD013551-bbs2-0061" title="CartmillM , DolanG , ByrneJL , ByrnePO . Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. British Journal of Neurosurgery2000;14(5):458-61.">Cartmill 2000</a>). Furthermore, FFP correction is also delayed due to prescription, cross‐matching and administration time (<a href="./references#CD013551-bbs2-0057" title="BordeleauS , PoitrasJ , MarceauD , BretonC , BeaupreP , ArchambaultPM . Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays. BMC Health Services Research 2015 Mar 15 [Epub ahead of print];15:106. [DOI: 10.1186/s12913-015-0775-6]">Bordeleau 2015</a>), and it is unable to correct an INR to less than 1.6 (<a href="./references#CD013551-bbs2-0112" title="YazerMH . The how's and why's of evidence based plasma therapy. Korean Journal of Hematology2010;45(3):152-7.">Yazer 2010</a>). </p> <p>FFP contains all the coagulation factors except platelets. It is the plasma portion of a unit of whole blood that is frozen. FFP contains all coagulation factors and other plasma proteins (albumin), including fibrinogen (400 to 900 mg/unit), physiological anticoagulants (protein C and S, antithrombin and tissue factor pathway inhibitor). Following thawing of FFP, factors V and VIII have a gradual decline requiring re‐administration if there is ongoing bleeding (<a href="./references#CD013551-bbs2-0087" title="NascimentoB , CallumJ , RubenfeldG , NetoJR , LinY , RizoliS . Clinical review: fresh frozen plasma in massive bleedings - more questions than answers. Critical Care2010;14(1):202.">Nascimento 2010</a>).  </p> <p>In comparison, following administration of PCC, there is correction of vitamin K‐dependent coagulation factors II, VII, IX and X and antithrombotic proteins C and S (in 4‐factor PCC). The 3‐factor PCC contains only factors II, IX and X with generally small amounts of factor VII, antithrombin and small amounts of heparin. Following increase of these substrate coagulation proteins, there is enhanced thrombin generation, which illustrates the ability of PCC to support the enzyme complexes that convert factor II to IIa (<a href="./references#CD013551-bbs2-0071" title="GhadimiK , LevyJH , WelsbyIJ . Prothrombin complex concentrates for bleeding in the perioperative setting. Anesthesia and Analgesia2016;122(5):1287-300.">Ghadimi 2016</a>). </p> <p>Factor VII is converted to VIIa and binds to tissue factor, which then activates factor IX and the primary coagulation pathway. Factor IX in the presence of VIIIa activates factor X. Factor X is activated to convert prothrombin to thrombin in the presence of phospholipids and calcium ions. Factor II is converted to thrombin by the presence of activated factor X. Thrombin converts fibrinogen to fibrin which is the substance of the clot, and activates factors VIII, V and XI to continue the coagulation pathway. Protein C is activated by thrombin to then exert an antithrombotic effect, whereas protein S exists in a free form as a cofactor for activated protein C (<a href="./references#CD013551-bbs2-0071" title="GhadimiK , LevyJH , WelsbyIJ . Prothrombin complex concentrates for bleeding in the perioperative setting. Anesthesia and Analgesia2016;122(5):1287-300.">Ghadimi 2016</a>). </p> <p>FFP has the advantage of containing all the required factors but in a dilute form, and large volumes are required for relatively small increments in factor levels. Conversely, PCC increases the key factors to a much larger extent. PCC is the ideal reversal agent of warfarin as the depleted factors are the vitamin K‐dependent ones. </p> </section> <section id="CD013551-sec-0013"> <h3 class="title" id="CD013551-sec-0013">Why it is important to do this review</h3> <p>Internationally, there is a growing collection of hospital‐based coagulation algorithms utilising PCC as factor replacement and as rescue therapy for the correction of coagulopathy post‐cardiac surgery. These centres mentioned are using PCC with point‐of‐care testing with thromboelastography such as rotational thromboelastometry (ROTEM) and thromboelastography (TEG). Montreal Heart Institute published their coagulation algorithm utilising PCC with ROTEM guidance with a dose of 10‐15 units/kg (<a href="./references#CD013551-bbs2-0064" title="DenaultA , LamarcheY , RochonA , CoganJ , LiszkowskiM , LebonJS , et al. Innovative approaches in the perioperative care of the cardiac surgical patient in the operating room and intensive care unit. Canadian Journal of Cardiology2014;30(12 Suppl):S459-77.">Denault 2014</a>). Duke University Hospital have recently published their algorithm (<a href="./references#CD013551-bbs2-0076" title="HashmiNK , GhadimiK , SrinivasanAJ , LiYJ , RaiffRD , GacaJG , et al. Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sanguinis2019;114(4):374-85.">Hashmi 2019</a>). Prince Charles hospital in Brisbane have also published an algorithm in association with National Blood Authority Australia (<a href="./references#CD013551-bbs2-0089" title="National Blood Authority Australia. Point of care coagulation testing. www.blood.gov.au/system/files/documents/%5BFinal%5D%20Point%20of%20Care%20Coagulation%20Testing%20Case%20Study.pdf (accessed 5 March 2020).">NBAA</a>). </p> <p>There are currently no randomised controlled trials (RCTs) in this area. There are, however, two trials listed on clinicaltrials.gov. One is a pilot in a single centre in London comparing FFP to PCC for patients who are bleeding during cardiac surgery (<a href="./references#CD013551-bbs2-0073" title="GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684.">Green 2019</a>). The other is a Mayo Clinic trial based in Rochester, sponsored by CSL Behring, looking at PCC compared to FFP for post‐cardiopulmonary bypass coagulopathy and bleeding (<a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a>). This second study utilises laboratory testing and not point‐of‐care coagulation testing. </p> <p>One publication, published in 2019, has stated that it is a “systematic review and meta‐analysis”, and it identified four studies to analyse with a total of 861 adult participants, none of which were randomised. The four studies that the authors included were all retrospective cohorts. The authors concluded that PCC appeared to be more effective than FFP in reducing perioperative blood transfusions and with no additional risk of thromboembolic events (<a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a>). The studies identified only included the one comparator, which was FFP, and it was limited to adults. In this growing area of research, there are additional studies that need to be included. </p> <p>This review would be the first step in summarising the entire literature in order to perform a comprehensive study that will assist in coagulation management and lead on to creating an international guideline. We believe that, with the introduction of PCC, there should be robust literature to support its use. PCC is potentially a very effective treatment option, which may reduce incidence of organ dysfunction, reduce blood transfusion and postoperative bleeding. It is cost‐effective but its safety and side effects need to be established before this becomes standard treatment worldwide. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013551-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013551-sec-0014"></div> <p>To assess the benefits and harms of prothrombin complex concentrate in people undergoing cardiac surgery who have coagulopathic non‐surgical bleeding </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013551-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013551-sec-0015"></div> <section id="CD013551-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013551-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included individual randomised controlled trials (RCTs) with both blinded and unblinded assessment of outcome. We did not include cluster‐ and cross‐over RCTs. Due to the low incidence of patients that could potentially benefit, this treatment is more likely to be studied in non‐randomised studies. </p> <p>In conjunction with these studies, we included non‐randomised trials: cohort trials, both prospective and retrospective in design; case‐control studies, as this is a reasonable study design to use, due to the rarity of the patients undergoing this procedure; and before‐and‐after studies, as the research may have occurred when hospitals changed their guidelines or policies. As this treatment is already in practice, it is important to summarise the current available evidence. Studies must analyse our described intervention and, if possible, compare with FFP or recombinant factor VIIa, or both. </p> <p>For the non‐randomised studies, we chose the most robust designs that we believe will be able to answer the question of interest with minimal risk of bias. We did not exclude studies on the basis of language of publication or publication status. We excluded animal studies and non‐clinical trials (in vitro, ex vivo, in vivo and in silico). </p> <p>We included case reports, which included outcomes on adverse events.</p> </section> <section id="CD013551-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies with participants of all age groups undergoing cardiac surgery who had coagulopathic bleeding (coagulopathy post‐cardiopulmonary bypass). </p> <p>We excluded studies that used PCC for reversal of warfarin or vitamin K antagonists, and preoperative haemorrhagic diathesis (for example, haemophilia A and B, myelodysplastic syndrome, von Willebrand disease, immune thrombocytopenic purpura). </p> <p>We believe that part of the resultant coagulopathy is a consequence of cardiopulmonary bypass, consequently, we will exclude any off‐pump cardiac surgery. </p> <p>If we cannot separate participants from cardiac surgery and other forms of surgery, then we will write to the study authors to obtain data. As long as 80% were cardiac patients, data from these studies would be included. </p> </section> <section id="CD013551-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies where PCC was prescribed for the intended purpose of factor replacement, as first‐line or rescue therapy (last‐resort therapy for refractory bleeding), or both, to reduce coagulopathic bleeding. There are many forms of PCC available internationally and we will review both 3‐ and 4‐factor products (<a href="./appendices#CD013551-sec-0100">Appendix 1</a>). We excluded single‐factor concentrates labelled 'prothrombin complex concentrates'. </p> <p>Comparators included standard therapy (current institutional protocol for bleeding diathesis), FFP and recombinant factor VIIa. </p> <p>We included studies that used PCC as monotherapy and also PCC in combination with FFP (delivery separately or together) for the same intended therapeutic effect (reduction in coagulopathic bleeding). We included studies with any described doses providing that they gave our intervention and comparators intravenously. We excluded studies using or comparing activated PCC because it contains an activated form of factor VII and this would cause confounding since recombinant factor VIIa is one of our direct comparators. </p> <p>The possibility that patients that receive PCC are likely to be higher risk of perioperative mortality and coagulopathy is a confounding factor. Factors that define high risk are defined further in the analysis section. </p> </section> <section id="CD013551-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD013551-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013551-list-0002"> <li> <p>Blood products transfused: defined as all products (whole blood, red blood cells, FFP, cryoprecipitate, platelets and fibrinogen concentrate) transfused in theatre and postoperatively, before and after the intervention or comparator, within 24 hours (mLs) </p> </li> <li> <p>Thrombotic events: defined as new venous and arterial thromboses within 30 days</p> </li> <li> <p>Mortality: defined as all‐cause mortality following cardiac surgery within 30 days</p> </li> </ol> </p> </section> <section id="CD013551-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013551-list-0003"> <li> <p>Bleeding: reviewed by postoperative drain output in the intensive care unit. We will not use intraoperative blood loss as a primary outcome for bleeding because it is poorly mentioned in the literature following cardiac surgery. Drain output is defined as total blood loss from the mediastinal and pleural drains in the first 12 hours (mLs). </p> </li> <li> <p>Intensive care unit length of stay: defined as the total stay in intensive care following surgery (hours) </p> </li> <li> <p>Incidence of renal impairment: defined as new or acute renal impairment requiring temporary continuous renal replacement therapy or sustained low‐efficiency daily diafiltration within 30 days </p> </li> <li> <p>Ventilator hours: the duration of intubation while in the intensive care unit</p> </li> <li> <p>Adverse events: any other adverse event reported within the primary studies not included in the above outcomes </p> </li> </ol> </p> </section> </section> </section> <section id="CD013551-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013551-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases to identify relevant studies on 20 April 2021: </p> <p> <ol id="CD013551-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (Issue 3 of 12, 2021); </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 19 April 2021); </p> </li> <li> <p>Embase (Ovid, 1980 to 2021 week 15);</p> </li> <li> <p>Conference Proceedings Citation Index‐Science (CPCI‐S) on the Web of Science (Clarivate Analytics, 1990 to 19 April 2021). </p> </li> </ol> </p> <p>We searched Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), and the World Health Organisation (WHO), International Clinical Trials Registry platform (ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>), for ongoing or unpublished trials on 10/02/2022 using the terms 'prothrombin complex concentrate' and 'cardiac surgery'. </p> <p>The preliminary search strategy for MEDLINE was adapted for the other databases (<a href="./appendices#CD013551-sec-0101">Appendix 2</a>). There was production and use of PCC prior to 2000, however, these PCCs are known to have different constituents and posed an increased thrombosis risk (<a href="./references#CD013551-bbs2-0084" title="KöhlerM . Thrombogenicity of prothrombin complex concentrates. Thrombosis Research1999;95(4 Suppl 1):S13-7.">Köhler 1999</a>), therefore, we have chosen to start the literature search from 2000. This is in relation to the European Medicines Authority (EMA) gaining regulatory approval in 2005 (<a href="./references#CD013551-bbs2-0067" title="European Medicine Authority. Committee for Medical Products for Human Use (CHMP) core SPC for human prothrombin complex products (CPMP/BPWG/3735/02). www.ema.europa.eu/en/documents/scientific-guideline/core-spc-human-prothrombin-complex-products-cpmp/bpwg/3735/02_en.pdf (accessed 5 March 2020).">European Medicine Authority</a>). </p> <p>We imposed no restriction on language of publication or publication status. We did not perform a separate search for adverse effects of interventions used for the treatment of coagulopathy post‐cardiopulmonary bypass. We considered adverse effects described in included studies only. </p> </section> <section id="CD013551-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references. We also contacted principal investigators of identified studies to ascertain if they were aware of any other relevant published or unpublished matching clinical studies. </p> </section> </section> <section id="CD013551-sec-0026"> <h3 class="title" id="CD013551-sec-0026">Data collection and analysis</h3> <section id="CD013551-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KH and CF) independently screened titles and abstracts for inclusion of all the potential studies we identified as a result of the search using Covidence and coded them as 'yes include' (eligible or potentially eligible/unclear), 'do not include', or 'maybe' if full text was required to clarify (<a href="./references#CD013551-bbs2-0062" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 5 March 2020. Available at covidence.org.">Covidence</a>). We resolved any disagreements about abstract suitability by discussion and consensus or a third party decision (VJ). We retrieved the full‐text study reports or publication and two review authors (KH and CF) independently screened the full text and identified studies for inclusion; we also identified and recorded reasons for exclusion of the ineligible studies. We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and '<a href="./references#CD013551-sec-0111" title="">Characteristics of included studies</a>' table (<a href="./references#CD013551-bbs2-0086" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009;6(7):e1000100.">Liberati 2009</a>). </p> </section> <section id="CD013551-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data, which had been piloted on at least one study in the review. Two review authors (KH and MF) extracted study characteristics from included studies separately and then compared and resolved conflicts. We extracted the following study characteristics. </p> <p> <ol id="CD013551-list-0005"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and location, study setting, and date of study. For cohort and case control studies, we collected information about where the control group was sourced. For the cohorts, we determined whether they were retrospective or prospective in design. </p> </li> <li> <p>Participants: number randomised, number lost to follow‐up or withdrawn, number analysed, mean age, age range, gender, inclusion criteria, and exclusion criteria. Cardiac‐specific data that we collected includes: type of cardiac surgery, duration of cardiopulmonary bypass, deep hypothermic arrest required, emergency surgery, pre‐operative anticoagulants, redo surgery and, when available, laboratory coagulation test results and point‐of‐care test results. </p> </li> <li> <p>Interventions: interventions and comparisons; we also planned to include any information regarding co‐interventions, though we did not expect any co‐interventions at this stage. </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. We also collected both adjusted and unadjusted data. When collecting the adjusted data, we noted what variables that the data had been adjusted for. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of study authors.</p> </li> </ol> </p> <p>Two review authors (KH, MF) independently extracted outcome data from included studies. We resolved disagreements by consensus. One review author (KH) transferred data into the Review Manager 5 (<a href="./references#CD013551-bbs2-0097" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, the Cochrane Collaboration, 2014.">Review Manager 2014</a>) file. We then double‐checked that data were entered correctly by comparing the data presented in the systematic review with the data extraction form. </p> </section> <section id="CD013551-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (KH and MF) independently assessed risk of bias, in both RCTs and NRSs, for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013551-bbs2-0078" title="HigginsJP , AltmanDG , Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions, version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). </p> <p> For RCTs, we assessed the risk of bias according to the following domains.</p> <p> <ol id="CD013551-list-0006"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear and provided a quote from the study report together with a justification for our judgement in the risk of bias table for RCTs and in a supplementary table for non‐RCTs. We summarised the risk of bias judgements across different studies for each of the domains listed. Where information on risk of bias related to unpublished data or correspondence with a study author, we noted this in the risk of bias table. </p> <p>For non‐RCTs, we used the ROBINS‐I tool (version 19 September 2016) for assessing the bias (<a href="./references#CD013551-bbs2-0104" title="SterneJA , HernanMA , ReevesBC , SavovicJ , BerkmanND , ViswanathanM , et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.">Sterne 2016</a>). This tool shows substantial overlap with the risk of bias ratings in RCTs, but additionally includes two domains at the pre‐intervention level (bias due to confounding, bias in selection of participants into the study), and one domain at the intervention level (bias in classification of interventions). This tool uses a five‐point scale (low/moderate/serious/critical/unclear risk) for the assessment of bias in non‐randomised studies of interventions (NRSI). The ROBINS‐I tool was used to asses the effect of the assignment. The primary analysis included all studies regardless of their risk of bias. Please see <a href="#CD013551-sec-0037">Sensitivity analysis</a> for how studies with serious and critical risk of bias were dealt with.   </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. Risk of bias in NRSs was assessed for all outcomes which had included studies; please see Additional tables. </p> <p>The most important confounding domains were those factors that increased the risk of bleeding. The factors affecting this are: </p> <p> <ol id="CD013551-list-0007"> <li> <p>age over 75 years</p> </li> <li> <p>active endocarditis</p> </li> <li> <p>redo surgery</p> </li> <li> <p>more than one cardiac surgical procedure</p> </li> </ol> </p> <p>All of these factors are covered in the EuroSCORE II (<a href="./references#CD013551-bbs2-0088" title="NashefSA , RoquesF , SharplesLD , NilssonJ , SmithC , GoldstoneAR , et al. EuroSCORE II. European Journal of Cardiothoracic Surgery2012;41(4):734-45.">Nashef 2012</a>). However, in addition to these EuroSCORE II factors, there are also these factors: </p> <p> <ol id="CD013551-list-0008"> <li> <p>Use of deep hypothermic cardiopulmonary arrest</p> </li> <li> <p>CBP more than 180 minutes</p> </li> <li> <p>BMI less than 25</p> </li> <li> <p>urgent/emergent</p> </li> <li> <p>pre‐operative anticoagulants</p> </li> <li> <p>aortic surgical work</p> </li> <li> <p>pre‐operative anaemia</p> </li> <li> <p>aortic valve disease (regurgitation/stenosis/both)</p> </li> <li> <p>history of thrombosis or coagulation defect</p> </li> </ol> </p> </section> <section id="CD013551-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For data supplied by a randomised controlled trial, we analysed continuous data as mean difference (MD) with 95% CI. We entered data presented as a scale with a consistent direction of effect. We measured dichotomous data with odds ratios (ORs). If data were presented as medians, we used the Bland Method to estimate means and standard deviations (<a href="./references#CD013551-bbs2-0111" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;14:135.">Wan 2014</a>). </p> <p>For non randomised studies, where possible, we chose adjusted over unadjusted estimates. We collected adjusted odds ratios (ORs) by preference, with 95% confidence intervals (CIs) from the NRSIs and, if adjusted data were not available, we collected unadjusted ORs with 95% CIs. If adjusted data were supplied by the NRSIs, we analysed these using generic inverse variance by using log ORs and standard errors. We noted adjustments made by the individual studies within the footnote section of the forest plot. </p> <p>We narratively described skewed data reported as medians and interquartile ranges.</p> </section> <section id="CD013551-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>Cross‐over studies and cluster‐RCTs were not included. For the outcomes where information was described as overall measures, that is, number of units of blood transfused and hours of hospital stay, we extracted these as mean numbers per person to avoid unit of analysis issues. </p> <p>For multiple time points, we used the outcome that was closest to the prespecified outcome measure. For NRSIs, when multiple adjusted estimates were reported, we chose the one that was judged to minimise the risk of bias due to confounding. </p> </section> <section id="CD013551-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data, where possible (e.g. when we identified a study that was only available as an abstract). We used the Review Manager 5 (<a href="./references#CD013551-bbs2-0097" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, the Cochrane Collaboration, 2014.">Review Manager 2014</a>) calculator to calculate missing standard deviations using other data from the study, such as confidence intervals, based on methods outlined in <i>The Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013551-bbs2-0079" title="HigginsJP , LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019), Cochrane 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). When this was not possible, and we thought that the missing data would introduce serious bias, we explored the impact of including such studies in the overall assessment of results by a sensitivity analysis. We addressed the potential impact of the missing data in our discussion. </p> </section> <section id="CD013551-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>Any variability among the studies in a systematic review may be caused by clinical, methodological or statistical heterogeneity. Any variability in the participants, interventions and outcomes studied were described as clinical diversity and any variability in the study design and risk of bias were described as methodological diversity (<a href="./references#CD013551-bbs2-0063" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). Variability from the intervention effects studied is known as statistical heterogeneity (referred to simply as heterogeneity) and can be a consequence of clinical or methodological diversity, or both. This may result in the observed intervention effects being more different from each other than one would expect due to random error alone (<a href="./references#CD013551-bbs2-0063" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). </p> <p>With the known lack of RCTs on the topic to be reviewed, we expected to see heterogeneity due to both clinical and methodological diversity. </p> <p>We inspected forest plots visually to consider the direction and magnitude of effects and the degree of overlap between confidence intervals. We used the I² statistic (<a href="./references#CD013551-bbs2-0077" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), to measure heterogeneity among the studies in each analysis but, acknowledging that there is substantial uncertainty in the value of the I² statistic when there is only a small number of studies, we also considered the P value from the Chi² test. </p> <p>When we identified substantial heterogeneity greater than 50%, we reported it and explored possible causes by prespecified subgroup analysis (<a href="./references#CD013551-bbs2-0063" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). </p> </section> <section id="CD013551-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>If we were able to pool more than 10 studies, we created and examined a funnel plot to explore possible small study biases for the primary outcomes (<a href="./references#CD013551-bbs2-0095" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019), Cochrane 2019. Available from www.training.cochrane.org/handbook.">Page 2019</a>). </p> </section> <section id="CD013551-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 (<a href="./references#CD013551-bbs2-0097" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, the Cochrane Collaboration, 2014.">Review Manager 2014</a>). We undertook meta‐analyses only where this was meaningful, that is, the treatments, participants and the underlying clinical questions were similar enough for pooling to make sense. We used a random‐effects model as we anticipated heterogeneity in the participant or intervention characteristics. We carried out separate meta‐analysis for RCTs and NRSIs. </p> <p>We analysed separately NRSIs with different study features.</p> <p>If data were unavailable to be pooled, we presented them in a narrative summary with tables, if appropriate. </p> </section> <section id="CD013551-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We carried out the following subgroup analyses.</p> <p> <ol id="CD013551-list-0009"> <li> <p>High risk for coagulopathy versus low risk for coagulopathy. For the definition of high risk versus low risk we relied on the definition of the primary studies. </p> </li> <li> <p>Use of PCC for rescue treatment in refractory bleeding versus recombinant factor VIIa</p> </li> <li> <p>Adults (&gt; 18 years) versus children (0‐18 years)</p> </li> <li> <p>Four‐factor PCC versus three‐factor PCC</p> </li> </ol> </p> <p>We used the formal test for subgroup differences in Review Manager 5 (<a href="./references#CD013551-bbs2-0097" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, the Cochrane Collaboration, 2014.">Review Manager 2014</a>), and based our interpretation on this. </p> </section> <section id="CD013551-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out the following sensitivity analyses, to test whether key methodological factors or decisions had affected the main result. </p> <p> <ol id="CD013551-list-0010"> <li> <p>For RCTs, we only included studies with a low risk of bias for selection bias and attrition. For the NRSIs, we undertook a sensitivity analysis looking at the studies deemed to be at an overall low to moderate risk of bias by the ROBINS‐I tool excluding those judged as serious and critical. </p> </li> <li> <p>We intended to carry out a sensitivity analysis on the inclusion of unadjusted data versus adjusted data but as no included studies supplied adjusted data, we did this for matched vs unmatched. </p> </li> <li> <p>We carried out a sensitivity analysis on the impact of missing data, excluding studies judged at high risk for missing data. </p> </li> <li> <p>We carried out a sensitivity analysis for NRSIs, looking at different study design features (if pooled). </p> </li> </ol> </p> </section> <section id="CD013551-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a summary of findings table using the following outcomes.</p> <p> <ol id="CD013551-list-0011"> <li> <p>Blood products transfused</p> </li> <li> <p>Thrombotic events</p> </li> <li> <p>Mortality</p> </li> <li> <p>Bleeding</p> </li> <li> <p>Intensive care unit length of stay</p> </li> <li> <p>Incidence of renal impairment</p> </li> <li> <p>Adverse events</p> </li> </ol> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it related to the studies that contributed data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013551-bbs2-0100" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019), Cochrane 2019. Available from www.training.cochrane.org/handbook.">Schünemann 2019a</a>) using GRADEpro software (<a href="./references#CD013551-bbs2-0072" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed after 2 March 2020. Available at gradepro.org.">GRADEpro GDT</a>). We created different summary of findings tables for RCTs and NRSIs. </p> <p>We compared both of the two comparators, FFP and recombinant factor VIIa, to PCC. We developed a separate summary of findings table for each comparison and we analysed each comparison separately. We justified all decisions to downgrade the quality of studies using footnotes and made comments to aid readers' understanding of the review, where necessary. </p> <p>Two review authors (KH and CF) worked independently to judge evidence quality, and resolved any disagreements by discussion or by involving a third review author, VJ. We justified and documented our judgements and incorporated them into reporting of results for each outcome. We made our judgements in accordance with recommendations on how the ROBINS‐I tool should integrate with GRADE. Evidence started at high quality and was downgraded according to the five domains that can lower certainty (<a href="./references#CD013551-bbs2-0101" title="SchünemannHJ , CuelloC , AklEA , MustafaRA , MeerpohlJJ , ThayerK , et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. Journal of Clinical Epidemiology2019;111:105-14.">Schünemann 2019b</a>). </p> <p>We extracted study data, formatted our comparisons in data tables and prepared a summary of findings table before writing the results and conclusions of our review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013551-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013551-sec-0039"></div> <section id="CD013551-sec-0040"> <h3 class="title">Description of studies</h3> <p>We provide descriptions of previously mentioned studies in the <a href="./references#CD013551-sec-0111" title="">Characteristics of included studies</a>, <a href="./references#CD013551-sec-0112" title="">Characteristics of excluded studies</a> and <a href="./references#CD013551-sec-0113" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD013551-sec-0041"> <h4 class="title">Results of the search</h4> <p>The search was performed on the 20 April 2021. The searches resulted in 1112 citations and an additional three papers were obtained from ongoing trials. None were identified from reviewing reference lists of included studies. </p> <p>From the 1112 citations, 1055 were irrelevant. The remaining 57 studies underwent full‐text screening, of which 18 were included. Amongst the 33 excluded studies, 20 of these had incorrect study design, 10 wrong participant population, two wrong intervention, one wrong comparator and three studies are still ongoing (<a href="#CD013551-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013551-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013551-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>Of the 18 included studies, one of these was later excluded as no data could be obtained during the 10‐year period during which the study was conducted.   </p> </section> <section id="CD013551-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD013551-sec-0043"> <h5 class="title">Design</h5> <p>Two pilot RCTs were included (<a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>; <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>) with nine months duration. </p> <p>Fourteen non‐randomised (NRS) retrospective cohort analyses were included (<a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a>; <a href="./references#CD013551-bbs2-0002" title="ArnekianV , CamousJ , FattalS , Rezaiguia-DelclauxS , NottinR , StephanF . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2012;15(3):382-9. ">Arnekian 2012</a>; <a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a>; <a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0007" title="FraserTA , CorkeCF , MohajeriM , StevensonL , CampbellPJ . A retrospective audit of the use of Prothrombinex-HT for refractory bleeding following adult cardiac surgery. Critical Care and Resuscitation2006;8(2):141-5. ">Fraser 2006</a>; <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0012" title="HashmiNK , GhadimiK , SchroderJ , LevyJ , WelsbyIJ . Three factor prothrombin complex concentrates in cardiac surgery: a novel algorithmic approach to perioperative bleeding. Blood2016;128(22):5035. HashmiNK , GhadimiK , SrinivasanAJ , LiYJ , RaiffRD , GacaJG , et al. Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sanguinis2019;114(4):374-85. ">Hashmi 2019</a>; <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>; <a href="./references#CD013551-bbs2-0016" title="RybkaMM , SamsonovaNN , KlimovichLG , RogalskayaEA , KhichagovDY , TataryanFE . Correction of hemostasis with blood products in the surgical treatment of congenital heart disease in infants and young children. Anesteziologiia i Reanimatologiia2015;60(5):42-6. ">Rybka 2015</a>; <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>). One prospective study (<a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>) and one case report of an adverse event (<a href="./references#CD013551-bbs2-0014" title="KosterA , Meyer-JarkT , SchirmerU , SandicaE . Fulminant intraoperative right heart and pulmonary artery thrombosis following prothrombin complex concentrate infusion after complex open heart surgery with cardiopulmonary bypass. A and A Case Reports2014;2(8):89-91. ">Koster 2014</a>) were included. The study duration ranged from seven months to nine years with two years median study duration.   </p> </section> <section id="CD013551-sec-0044"> <h5 class="title">Sample</h5> <p>The pilot RCTs had a total of 151 participants consisting of 50 <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> and 101 <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>. The NRS had a total of 4842 participants with varying sample sizes, the largest pre‐matching being <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> (1355 patients) and the smallest being <a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a> (25 patients). <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> analysed the largest series of post‐propensity matched patients with 450. There were no single‐sex studies and age distribution was an adequate representation of those undergoing cardiac surgery. There were 1986 post‐propensity matched studies that included 1312 (66%) men and 674 (34%) women. </p> </section> <section id="CD013551-sec-0045"> <h5 class="title">Location</h5> <p>Most studies had single‐centre design except one that was conducted in multiple countries. Six studies were conducted in the USA (<a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a>, <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>, <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>, <a href="./references#CD013551-bbs2-0012" title="HashmiNK , GhadimiK , SchroderJ , LevyJ , WelsbyIJ . Three factor prothrombin complex concentrates in cardiac surgery: a novel algorithmic approach to perioperative bleeding. Blood2016;128(22):5035. HashmiNK , GhadimiK , SrinivasanAJ , LiYJ , RaiffRD , GacaJG , et al. Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sanguinis2019;114(4):374-85. ">Hashmi 2019</a>, <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>, <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>), and two were conducted in Italy (<a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>, <a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>), Australia (<a href="./references#CD013551-bbs2-0007" title="FraserTA , CorkeCF , MohajeriM , StevensonL , CampbellPJ . A retrospective audit of the use of Prothrombinex-HT for refractory bleeding following adult cardiac surgery. Critical Care and Resuscitation2006;8(2):141-5. ">Fraser 2006</a>, <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>), Canada (<a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>, <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>) and the United Kingdom (<a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a>, <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>). One study each was included: from France (<a href="./references#CD013551-bbs2-0002" title="ArnekianV , CamousJ , FattalS , Rezaiguia-DelclauxS , NottinR , StephanF . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2012;15(3):382-9. ">Arnekian 2012</a>), Germany (<a href="./references#CD013551-bbs2-0014" title="KosterA , Meyer-JarkT , SchirmerU , SandicaE . Fulminant intraoperative right heart and pulmonary artery thrombosis following prothrombin complex concentrate infusion after complex open heart surgery with cardiopulmonary bypass. A and A Case Reports2014;2(8):89-91. ">Koster 2014</a>), and Russia (<a href="./references#CD013551-bbs2-0016" title="RybkaMM , SamsonovaNN , KlimovichLG , RogalskayaEA , KhichagovDY , TataryanFE . Correction of hemostasis with blood products in the surgical treatment of congenital heart disease in infants and young children. Anesteziologiia i Reanimatologiia2015;60(5):42-6. ">Rybka 2015</a>). One multicentre study (<a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>) included patients across nine centres in Finland, France, Italy, Germany, Sweden and United Kingdom. </p> </section> <section id="CD013551-sec-0046"> <h5 class="title">Participants</h5> <section id="CD013551-sec-0047"> <h6 class="title">Age and gender</h6> <p>Three studies reviewed paediatric patients (<a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>, <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>, <a href="./references#CD013551-bbs2-0016" title="RybkaMM , SamsonovaNN , KlimovichLG , RogalskayaEA , KhichagovDY , TataryanFE . Correction of hemostasis with blood products in the surgical treatment of congenital heart disease in infants and young children. Anesteziologiia i Reanimatologiia2015;60(5):42-6. ">Rybka 2015</a>), with <a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a> having mean age of 13 days  and 17 days in the intervention and comparison group, respectively, and <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> a mean age of 164 days and 139 days in the intervention and comparison group, respectively. The remaining 15 studies (<a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a>; <a href="./references#CD013551-bbs2-0002" title="ArnekianV , CamousJ , FattalS , Rezaiguia-DelclauxS , NottinR , StephanF . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2012;15(3):382-9. ">Arnekian 2012</a>; <a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a>; <a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>; <a href="./references#CD013551-bbs2-0007" title="FraserTA , CorkeCF , MohajeriM , StevensonL , CampbellPJ . A retrospective audit of the use of Prothrombinex-HT for refractory bleeding following adult cardiac surgery. Critical Care and Resuscitation2006;8(2):141-5. ">Fraser 2006</a>; <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>; <a href="./references#CD013551-bbs2-0012" title="HashmiNK , GhadimiK , SchroderJ , LevyJ , WelsbyIJ . Three factor prothrombin complex concentrates in cardiac surgery: a novel algorithmic approach to perioperative bleeding. Blood2016;128(22):5035. HashmiNK , GhadimiK , SrinivasanAJ , LiYJ , RaiffRD , GacaJG , et al. Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sanguinis2019;114(4):374-85. ">Hashmi 2019</a>; <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>; <a href="./references#CD013551-bbs2-0014" title="KosterA , Meyer-JarkT , SchirmerU , SandicaE . Fulminant intraoperative right heart and pulmonary artery thrombosis following prothrombin complex concentrate infusion after complex open heart surgery with cardiopulmonary bypass. A and A Case Reports2014;2(8):89-91. ">Koster 2014</a>; <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>; <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>) reviewed adult patients, with a mean age in the intervention group of 63 years and in the comparison group 64 years. The gener proportion of the population was 69% male and 31% female. </p> </section> </section> <section id="CD013551-sec-0048"> <h5 class="title">Comparison</h5> <p>Eleven studies compared PCC to standard therapy. This included PCC compared to FFP alone, PCC and FFP compared to FFP alone, and PCC compared to an institutional transfusion therapy protocol. </p> <p>Two RCTs compared PCCs to FFP. <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> randomised only one dose of PCCs, whereas <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> had up to two doses of PCCs; both studies then instituted standard practice with FFP following the intervention if further factor replacement was required.   </p> <p>Of the NRSs, two studies compared PCCs to FFP alone (<a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a> and <a href="./references#CD013551-bbs2-0002" title="ArnekianV , CamousJ , FattalS , Rezaiguia-DelclauxS , NottinR , StephanF . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2012;15(3):382-9. ">Arnekian 2012</a>), five studies compared PCCs and FFP to FFP alone (<a href="./references#CD013551-bbs2-0002" title="ArnekianV , CamousJ , FattalS , Rezaiguia-DelclauxS , NottinR , StephanF . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2012;15(3):382-9. ">Arnekian 2012</a>, <a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>, <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>, <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> and <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>) and two studies compared PCCs to standard blood product transfusion therapy (<a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>). </p> <p>We identified five studies that compared PCCs to rFVIIa (<a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a>, <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>, <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>, <a href="./references#CD013551-bbs2-0016" title="RybkaMM , SamsonovaNN , KlimovichLG , RogalskayaEA , KhichagovDY , TataryanFE . Correction of hemostasis with blood products in the surgical treatment of congenital heart disease in infants and young children. Anesteziologiia i Reanimatologiia2015;60(5):42-6. ">Rybka 2015</a>, <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>). </p> <p>The remaining two studies reviewed PCCs alone without a comparator (<a href="./references#CD013551-bbs2-0007" title="FraserTA , CorkeCF , MohajeriM , StevensonL , CampbellPJ . A retrospective audit of the use of Prothrombinex-HT for refractory bleeding following adult cardiac surgery. Critical Care and Resuscitation2006;8(2):141-5. ">Fraser 2006</a>; <a href="./references#CD013551-bbs2-0012" title="HashmiNK , GhadimiK , SchroderJ , LevyJ , WelsbyIJ . Three factor prothrombin complex concentrates in cardiac surgery: a novel algorithmic approach to perioperative bleeding. Blood2016;128(22):5035. HashmiNK , GhadimiK , SrinivasanAJ , LiYJ , RaiffRD , GacaJG , et al. Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sanguinis2019;114(4):374-85. ">Hashmi 2019</a>). </p> </section> <section id="CD013551-sec-0049"> <h5 class="title">Intervention</h5> <p>All of our included studies used either 3‐factor or 4‐factor PCCs. Nine studies used 4‐factor PCCs (<a href="./references#CD013551-bbs2-0002" title="ArnekianV , CamousJ , FattalS , Rezaiguia-DelclauxS , NottinR , StephanF . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2012;15(3):382-9. ">Arnekian 2012</a>; <a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>; <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>; <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>; <a href="./references#CD013551-bbs2-0014" title="KosterA , Meyer-JarkT , SchirmerU , SandicaE . Fulminant intraoperative right heart and pulmonary artery thrombosis following prothrombin complex concentrate infusion after complex open heart surgery with cardiopulmonary bypass. A and A Case Reports2014;2(8):89-91. ">Koster 2014</a>; <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>; <a href="./references#CD013551-bbs2-0016" title="RybkaMM , SamsonovaNN , KlimovichLG , RogalskayaEA , KhichagovDY , TataryanFE . Correction of hemostasis with blood products in the surgical treatment of congenital heart disease in infants and young children. Anesteziologiia i Reanimatologiia2015;60(5):42-6. ">Rybka 2015</a>) and seven studies used 3‐factor PCCs (<a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0007" title="FraserTA , CorkeCF , MohajeriM , StevensonL , CampbellPJ . A retrospective audit of the use of Prothrombinex-HT for refractory bleeding following adult cardiac surgery. Critical Care and Resuscitation2006;8(2):141-5. ">Fraser 2006</a>; <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0012" title="HashmiNK , GhadimiK , SchroderJ , LevyJ , WelsbyIJ . Three factor prothrombin complex concentrates in cardiac surgery: a novel algorithmic approach to perioperative bleeding. Blood2016;128(22):5035. HashmiNK , GhadimiK , SrinivasanAJ , LiYJ , RaiffRD , GacaJG , et al. Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sanguinis2019;114(4):374-85. ">Hashmi 2019</a>; <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>). </p> <p>One study evaluated both 3‐ and 4‐factor PCCs (<a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>). One study did not provide the type of PCCs they reviewed (<a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a>). </p> </section> </section> <section id="CD013551-sec-0050"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD013551-sec-0112" title="">Characteristics of excluded studies</a>. </p> <p>We excluded 33 studies. Of these, 30 were excluded: 17 had incorrect study design, 10 wrong participant population, two wrong intervention and one wrong comparator. Three were ongoing studies. </p> <p>During our analysis, we had to exclude a further study (<a href="./references#CD013551-bbs2-0042" title="RanucciM , BaryshnikovaE , PistuddiV , MenicantiL , FrigiolaA , Surgical and Clinical Outcome REsearch (SCORE) Group. The effectiveness of 10 years of interventions to control postoperative bleeding in adult cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2017;24(2):196-202. ">Ranucci 2017</a>) as no data were obtainable due to a 10‐year study design. The study included a bundle of care which consisted of multiple interventions introduced over a 10‐year period. Data were not provided on the effect of the individual interventions.  </p> <section id="CD013551-sec-0051"> <h5 class="title">Ongoing Studies</h5> <p>The three ongoing studies are <a href="./references#CD013551-bbs2-0051" title="NCT02557672. PCC vs. FFP for post cardiopulmonary bypass coagulopathy and bleeding. clinicaltrials.gov/show/NCT02557672 (first received 23 September 2015). ">NCT02557672</a>; <a href="./references#CD013551-bbs2-0053" title="NCT04434001. ZEPLAST- PED: zEro_PLASma trial in small infants undergoing cardiac surgery. protect-au.mimecast.com/s/Uq9fCyoj4JiL8JwysR34FhX?domain=clinicaltrials.gov (first received 16 June 2020). ">NCT04434001</a>; and <a href="./references#CD013551-bbs2-0052" title="NCT04244981. Efficacy of prothrombin complex concentrate reducing perioperative blood loss in cardiac surgery. clinicaltrials.gov/show/NCT04244981 (first received 28 January 2020). ">NCT04244981</a>. </p> </section> </section> </section> <section id="CD013551-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD013551-sec-0053"> <h4 class="title">Randomised controlled studies:</h4> <p>The two RCTs had an overall low risk of bias; please see figures (<a href="#CD013551-fig-0002">Figure 2</a>; <a href="#CD013551-fig-0003">Figure 3</a>).    </p> <div class="figure" id="CD013551-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph for RCT studies: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD013551-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph for RCT studies: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD013551-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary for RCT studies: review authors' judgements about each risk of bias item for each included study" data-id="CD013551-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary for RCT studies: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> </section> <section id="CD013551-sec-0054"> <h4 class="title">Allocation</h4> <p>Both <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> and <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> had low risk of bias due to appropriate random allocation and concealment of allocation  of their participants into each treatment group.  </p> </section> <section id="CD013551-sec-0055"> <h4 class="title">Blinding</h4> <p>The intervention could not be blinded due to the different physical properties of the two products; both RCTs had a low risk of performance bias as outcomes were objective and judged to be at low risk of being influenced even with the knowledge of treatment allocation. In addition, <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> minimised this by the first set of products being released in weight‐matched, tamper‐sealed containers that were opened immediately before initiating treatment. </p> <p>For detection bias, both included RCTs were judged to be at low risk of bias. In <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>, although clinicians collecting the data were not blinded to the interventions, these objective outcomes could not be manipulated as a result of having this knowledge. In <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>, the clinicians were not involved in product administration, so they remained blinded to group assignment. </p> </section> <section id="CD013551-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> was judged at low risk of bias due to complete follow‐up and intention‐to‐treat analysis. <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> was judged as being at unclear risk of bias with up to 18% in the PCC group and 36% of in the FFP group not receiving their intervention despite being randomised. These patients were not included in the analysis. It did not appear to alter the baseline characteristics between the two groups, however, bias could have been introduced due to the low risk of bleeding patients being excluded as they stopped bleeding by the time the product arrived in the operating room.     </p> </section> <section id="CD013551-sec-0057"> <h4 class="title">Selective reporting</h4> <p>Both were at low risk of bias, with all outcomes from their protocol being measured. </p> </section> <section id="CD013551-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>No other bias was detected in either study. </p> <section id="CD013551-sec-0059"> <h5 class="title">Non‐randomised studies:</h5> <p>Overall, 10 studies had overall critical risk of bias (<a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a>; <a href="./references#CD013551-bbs2-0002" title="ArnekianV , CamousJ , FattalS , Rezaiguia-DelclauxS , NottinR , StephanF . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2012;15(3):382-9. ">Arnekian 2012</a>; <a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a>; <a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0007" title="FraserTA , CorkeCF , MohajeriM , StevensonL , CampbellPJ . A retrospective audit of the use of Prothrombinex-HT for refractory bleeding following adult cardiac surgery. Critical Care and Resuscitation2006;8(2):141-5. ">Fraser 2006</a>; <a href="./references#CD013551-bbs2-0012" title="HashmiNK , GhadimiK , SchroderJ , LevyJ , WelsbyIJ . Three factor prothrombin complex concentrates in cardiac surgery: a novel algorithmic approach to perioperative bleeding. Blood2016;128(22):5035. HashmiNK , GhadimiK , SrinivasanAJ , LiYJ , RaiffRD , GacaJG , et al. Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sanguinis2019;114(4):374-85. ">Hashmi 2019</a>; <a href="./references#CD013551-bbs2-0014" title="KosterA , Meyer-JarkT , SchirmerU , SandicaE . Fulminant intraoperative right heart and pulmonary artery thrombosis following prothrombin complex concentrate infusion after complex open heart surgery with cardiopulmonary bypass. A and A Case Reports2014;2(8):89-91. ">Koster 2014</a>; <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>; <a href="./references#CD013551-bbs2-0016" title="RybkaMM , SamsonovaNN , KlimovichLG , RogalskayaEA , KhichagovDY , TataryanFE . Correction of hemostasis with blood products in the surgical treatment of congenital heart disease in infants and young children. Anesteziologiia i Reanimatologiia2015;60(5):42-6. ">Rybka 2015</a>; <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>). Three studies had an overall serious risk of bias (<a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>; <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>). Three had a overall moderate risk of bias (<a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>). Risk of bias was judged separately for studies contributing to each outcome and these judgements are documented in the following figures (<a href="#CD013551-fig-0004">Figure 4</a>; <a href="#CD013551-fig-0005">Figure 5</a>; <a href="#CD013551-fig-0006">Figure 6</a>; <a href="#CD013551-fig-0007">Figure 7</a>; <a href="#CD013551-fig-0008">Figure 8</a>; <a href="#CD013551-fig-0009">Figure 9</a>; <a href="#CD013551-fig-0010">Figure 10</a>; <a href="#CD013551-fig-0011">Figure 11</a>; <a href="#CD013551-fig-0012">Figure 12</a>; <a href="#CD013551-fig-0013">Figure 13</a>; <a href="#CD013551-fig-0014">Figure 14</a>). Bias due to missing data and selection of reported results was judged low risk for the majority of studies as there were very few patients lost to follow‐up and most of the studies reported outcomes using appropriate methods. Bias due to confounding was the domain most likely to result in bias due to a lack of adequate control groups or appropriate analysis. For more information, please refer to the final paragraph in the <a href="#CD013551-sec-0060">Effects of interventions</a> section for each outcome. </p> <div class="figure" id="CD013551-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="NRS: Blood products transfused (RBC) % of patients " data-id="CD013551-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: Blood products transfused (RBC) % of patients </p> </div> </div> </div> <div class="figure" id="CD013551-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="NRS: PCCs thrombotic events " data-id="CD013551-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-05.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: PCCs thrombotic events </p> </div> </div> </div> <div class="figure" id="CD013551-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="NRS: PCCs mortality " data-id="CD013551-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-06.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: PCCs mortality </p> </div> </div> </div> <div class="figure" id="CD013551-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="NRS: PCCs ICU length of stay " data-id="CD013551-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-07.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: PCCs ICU length of stay </p> </div> </div> </div> <div class="figure" id="CD013551-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="NRS: PCCs renal replacement therapy " data-id="CD013551-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-08.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: PCCs renal replacement therapy </p> </div> </div> </div> <div class="figure" id="CD013551-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="NRS: PCCS ventilator duration" data-id="CD013551-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-09.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: PCCS ventilator duration</p> </div> </div> </div> <div class="figure" id="CD013551-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="NRS: Factor VIIa blood products transfused (RBC) % patients " data-id="CD013551-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-10.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: Factor VIIa blood products transfused (RBC) % patients </p> </div> </div> </div> <div class="figure" id="CD013551-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="NRS: Factor VIIa thrombotic events " data-id="CD013551-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-11.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: Factor VIIa thrombotic events </p> </div> </div> </div> <div class="figure" id="CD013551-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="NRS: Factor VIIa mortality " data-id="CD013551-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-12.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: Factor VIIa mortality </p> </div> </div> </div> <div class="figure" id="CD013551-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="NRS: Factor VIIa ICU length of stay " data-id="CD013551-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-13.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: Factor VIIa ICU length of stay </p> </div> </div> </div> <div class="figure" id="CD013551-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="NRS: Factor VIIa renal replacement therapy " data-id="CD013551-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-14.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>NRS: Factor VIIa renal replacement therapy </p> </div> </div> </div> </section> </section> </section> <section id="CD013551-sec-0060"> <h3 class="title" id="CD013551-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD013551-tbl-0001"><b>Summary of findings 1</b> PCC compared to standard treatment for cardiac surgery for the treatment of non‐surgical bleeding</a>; <a href="./full#CD013551-tbl-0002"><b>Summary of findings 2</b> PCC compared to FVIIa for cardiac surgery for the treatment of non‐surgical bleeding</a> </p> <p>For detailed analysis, see the summary of findings table for PCC compared to standard treatment (<a href="./full#CD013551-tbl-0001">summary of findings Table 1</a>) and for PCC compared to rFVIIa (<a href="./full#CD013551-tbl-0002">summary of findings Table 2</a>).  </p> <section id="CD013551-sec-0061"> <h4 class="title">1. PCC versus standard treatment</h4> <p><b>Blood products transfused</b> </p> <p>Two RCTs reported on red cell transfusion (<a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>; <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>). PCCs were likely to reduce the number of units transfused compared to standard care (MD ‐0.89, 95% CI ‐1.78 to 0.00; participants = 151; studies = 2; moderate‐quality evidence, I<sup>2</sup> = 0%; <a href="./references#CD013551-fig-0015" title="">Analysis 1.1</a>). </p> <p>Two NRS studies reported on red cell transfusion (<a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>). PCCs may reduce the mean number of units transfused compared to standard care but the evidence is uncertain (MD ‐1.87, 95% CI ‐2.53 to ‐1.20; participants = 551; studies = 2; very low‐quality evidence; I<sup>2</sup> = 0%; <a href="./references#CD013551-fig-0016" title="">Analysis 1.2</a>). Sensitivity and subgroup analysis were unable to be performed as a result of the low number of studies.   </p> <p>The risk of bias of these two studies were critical and moderate due to the inclusion of patients not undergoing cardiac surgery on cardiopulmonary bypass and multiple analysis methods (<a href="#CD013551-fig-0004">Figure 4</a>, <a href="#CD013551-tbl-0003">Table 1</a>). </p> <div class="table" id="CD013551-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for blood products (RBC) transfused</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intention of study was to review PCC vs FFP in patients undergoing cardiac surgery for CPB but they have included off‐CPB patients (FFP group 27% and PCC group 24%). </p> <p>‐ Propensity‐matching occurred (101 patients each group).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC +/‐ FFP or FFP alone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised heparin, protamine and TXA protocol</p> <p>‐ Clinically appropriate dose of PCC and FFP</p> <p>‐ No agreed coagulation algorithm amongst the hospitals</p> <p>‐ There was no decision‐making process around when to give intervention or comparison.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>Collected data from e‐CABG registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No multiple subgroup analysis. Reported on what their methods stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Critical bias in domain 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity‐matching</p> <p>‐ Important domains were measured and accounted for</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ This was not a deviation from standard practice.</p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Use of extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two types of analyses were conducted with differing results. For RBC transfused they used: propensity score‐matched pairs and propensity score‐adjusted.  </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p> </p> <p> </p> <p>‐ Unclear if 57 patients who received both interventions were included in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ There were matching patients in each intervention group</p> <p>‐ 69 patients in PCC group could not be matched due to being a higher‐risk population (emergency surgery, longer CPB time and complex surgery). </p> <p>‐ Two variables were not able to be matched with a SMD &lt; 10% (CPB time and diabetes).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs were all given intraoperatively and not in ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that PCC group were able to receive FFP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised care mentioned</p> <p>‐ Both groups received rFVIIa with no statistical significance between the groups.</p> <p>‐ POC testing and lab tests to guide transfusion requirements</p> <p>‐ PCCs were given according to a protocol.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 18 patients excluded due to missing data (8%)</p> <p>‐ Data were obtained from institutional databases.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on what their methods stated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unfortunate to not have 69 patients of higher complexity included in the study. We believe these patients would have provided objective evidence for the higher‐risk population group. </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity‐matched</p> <p> </p> <p>‐ No cross‐over occurred.</p> <p> </p> <p>‐ 18 patients unmatched (25%) from the PCC group because of more complex surgical procedure </p> <p> </p> <p>‐ Clear selection bias in choosing which patients received PCCs making it impossible to ascertain whether the complications observed were truly from the PCCs or the surgical complexity </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or clotting factor‐based therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unsure when intervention was given</p> <p>No mention of POC or lab tests</p> <p>No protocol</p> <p>The decision to give PCC was left up to the surgeon, anaesthetist, or intensivist</p> <p>Median dose of PCC 1500 units </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No reports of missing data.</p> <p> </p> <p>Collection of data ‐ from Austin hospital blood bank and cross‐referenced with the Australian Society of Cardiothoracic Surgeons database </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assessors were aware of the intervention group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity‐matched pairs were evaluated by a multivariate logistic regression model adjusted for age, sex, total units of RBC, cryoprecipitate, FFP and platelets combined. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p> </p> <p>‐ Unclear as to timing of interventions</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>CPB: Cardiopulmonary Bypass <br/>e‐CABG: electronic Coronary Artery Bypass Graft <br/>FFP: Fresh Frozen Plasma <br/>ICU: Intensive Care Unit <br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>POC: Point Of Care <br/>SMD: Standard Mean Difference <br/>TXA: Tranexamic Acid  </p> </div> </div> <p>One RCT reported on incidence of red cell transfusion (<a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>). There was no evidence from this study showing a difference in the incidence of RBC transfusion compared to standard care (OR 0.53, 95% CI 0.2 to 1.4; participants = 101; studies = 1; low‐quality evidence; <a href="./references#CD013551-fig-0017" title="">Analysis 1.3</a>). </p> <p>Four studies (<a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>) also reported the incidence of red cell transfusion. The evidence suggests PCC reduces the incidence of red cell transfusion compared to standard care but the evidence is uncertain (OR 0.54, 95% CI 0.30 to 0.98; participants = 1046; studies = 4; low‐quality evidence; I<sup>2</sup> = 63%; <a href="./references#CD013551-fig-0018" title="">Analysis 1.4</a>).   </p> <p>Sensitivity analysis was conducted on the incidence of red cell transfusion, by removing studies judged to be of serious and critical risk of bias. <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> and <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> showed no difference between PCC and standard treatment (OR 0.71; 95% CI 0.41 to 1.22, participants = 394; studies = 2). </p> <p>Removing studies that contained unadjusted data did not alter the outcome. </p> <p>The risk of bias for these four studies was critical for one and moderate for three; this is due to the inclusion of non‐cardiopulmonary bypass patients, a high proportion of the PCC groups being higher risk, and not able to be matched and therefore excluded in the matched data (<a href="#CD013551-fig-0004">Figure 4</a>, <a href="#CD013551-tbl-0003">Table 1</a>). </p> <section id="CD013551-sec-0062"> <h5 class="title">Thrombotic events</h5> <p>Two RCTs reported on thrombotic events (<a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>; <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>). There is no evidence from RCTs showing a difference in the number of thrombotic events with PCC compared to standard care (OR 0.68, 95% CI 0.2 to 2.31; participants = 151; studies = 2; moderate‐quality evidence; I<sup>2</sup> = 0%; <a href="./references#CD013551-fig-0019" title="">Analysis 1.5</a>). </p> <p>Seven NRSs (<a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a>; <a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>, <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>) reported on thrombotic events with a total of 1359 participants. One study (<a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>) did not report any events in either PCC or standard care group and so has not contributed to the meta‐analysis. PCC may have no effect on the number of thrombotic events compared to standard care but the evidence is very uncertain (OR 1.32, 95% CI 0.87 to 1.99; participants = 1359; studies = 7; very low‐quality evidence; I<sup>2</sup> = 0%; <a href="./references#CD013551-fig-0020" title="">Analysis 1.6</a>) . </p> <p>Six NRSs presented propensity matched data (<a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>) with an OR 1.33 (95% CI 0.87 to 2.01; participants = 1189; studies = 6; I<sup>2</sup> = 0%; low‐quality evidence). </p> <p>A sensitivity analysis reviewing thrombotic events in only trials considered to be of moderate risk of bias  (<a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>) provided an OR of 1.41 (95% CI 0.76 to 2.63, participants = 512; studies = 3). </p> <p>Subgroup analysis looking at 3‐factor versus 4‐factor PPC was conducted.  Four trials specified whether they were using 3‐ or 4‐factor PCC (<a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>). We found that the different type of PCC may have no effect on thrombotic outcomes with the test for subgroup differences showing no difference between these groups (test for subgroup differences: Chi² = 0.74, df = 1 (P = 0.39), I² = 0%); <a href="./references#CD013551-fig-0022" title="">Analysis 1.8</a>). </p> <p>The risk of bias for the seven NRSs were critical for two, serious for one and moderate for four studies; this is due to unmatched data, inclusion of non‐cardiopulmonary bypass participants, multiple analysis, inadequate matching, small sample sizes, and exclusion of high‐risk patients due to no appropriate match (<a href="#CD013551-fig-0005">Figure 5</a>, <a href="#CD013551-tbl-0004">Table 2</a>). </p> <div class="table" id="CD013551-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for thrombotic events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No matching occurred.</p> <p> </p> <p>‐ The PCC group had higher‐complexity surgery, duration and individual participant risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU, follow‐up may have started before intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No mention of dose given</p> <p>‐ No mention of co‐interventions</p> <p>‐ No mention of usual clinical practice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assumed this was low because the authors have not mentioned any missing data. No mention of how authors collected their data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group</p> <p>‐ Objective outcomes</p> <p>‐ Did not mention how they detected thrombosis and thrombotic events (i.e. clinically or radiological assessment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No multiple subgroup analysis Reported on what their methods stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>PCC patients were in a higher‐risk group</p> <p>No mention of doses, clinical practice and standard care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ The intention of study was to review PCC vs FFP in patients undergoing cardiac surgery on CPB but they have included off‐CPB patients (FFP group 27% and PCC group 24%) </p> <p>‐ Propensity matching occurred (101 patients each group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC +/‐ FFP or FFP alone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised heparin, protamine and TXA protocol</p> <p>‐ Clinically appropriate dose of PCC and FFP</p> <p>‐ No agreed coagulation algorithm amongst the hospitals</p> <p>‐ There was no decision‐making process around when to give intervention or comparison.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Three patients had missing data on the location of surgical bleeding</p> <p>‐ Collected data from e‐CABG registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective, assessors aware of intervention group</p> <p>‐ Objective outcomes</p> <p>‐ Discussed incidence of stroke but no mention how this was diagnosed (i.e. clinical or radiological) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No multiple subgroup analysis Reported on what their methods stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Critical bias in domain 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity matching</p> <p>‐ Important domains were measured and accounted for</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ This was not a deviation from standard practice.</p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group</p> <p>‐ Objective outcomes</p> <p>‐ Discussed incidence of stroke but no mention how this was diagnosed (i.e. clinical or radiological) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two types of analyses were conducted:</p> <p>propensity‐score adjusted and  propensity score‐matched </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>‐ Unclear if 57 patients who received both interventions were included in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ There was matching of patients in each intervention group</p> <p>‐ 69 patients in PCC group could not be matched due to being a higher‐risk population (emergency surgery, longer CPB time and complex surgery) </p> <p>‐ Two variables were not able to be matched with a SMD &lt; 10% (CPB time and diabetes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coinciding for all participants.</p> <p>PCCs all given intraoperatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that PCC group participants were able to receive FFP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised care mentioned</p> <p>‐ Both groups received rFVIIa with no statistical significance between the groups.</p> <p>‐ POC testing and lab tests to guide transfusion requirements</p> <p>‐ PCCs were given according to a protocol.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 18 patients excluded due to missing data (8%)</p> <p>‐ Data were obtained from institutional databases.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group</p> <p>‐ Objective outcomes</p> <p>Defined how they diagnosed stroke (clinically) and DVT/PE (radiological confirmation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unfortunate to not have 69 patients of higher complexity included in the study. We believe these patients would have provided objective evidence for the higher risk population group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Not propensity‐matched</p> <p>‐ The control group was a retrospectively‐matched cohort for baseline variables: "the treated and non‐treated patients were adequately matched for all the baseline variables" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection in the non‐PCC group and follow‐up coincided for all participants.</p> <p>PCCs all given in the OR. FFP usage similar between the two groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that PCC group participants were able to receive FFP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol for use of Confidex mentioned in methods</p> <p>Protocol stated how/when they received the standard treatment (FFP and cryo) vs PCCs.</p> <p>Used a clinically appropriate dose of PCC 25 u/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No mention of missing data</p> <p>‐ Prospective enrolment of the PCC group and data on excel spreadsheet. ‐ Unclear how they retrospectively obtained data for the control group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daily echo monitoring performed on all enrolled patients to exclude intracardiac thrombi. They did not do this for the retrospective control group. </p> <p> </p> <p>Not comparable assessment. Unclear if this resulted in significant differences because the PCC group had no incidence of intracardiac thrombi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Due to serious bias in confounding</p> <p> </p> <p>‐ Small sample size (14 patients in PCC group vs. 11 patients in control group)</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Matching occurred with a control based on demographic and surgical characteristics;</p> <p>6/65 patients could not be matched</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>All PCCs and their 1:1:1 blood products given in OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined intervention group and comparison group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unclear dose of protamine/antifibrinolytics</p> <p>‐ If bleeding they used a 1:1:1: transfusion as per protocol</p> <p>‐ Intervention used if ongoing bleeding despite transfusion; this was based on clinician judgement </p> <p>‐ Control group got standard therapy, intervention group got PCCs if they continued to bleed (potentially a higher‐risk population) </p> <p>‐ Unclear if they used POC testing or lab bloods</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Collection of data ‐ retrospective data base analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective, assessors aware of intervention group</p> <p>‐ Objective outcomes</p> <p>Thromboembolic events were analysed for clinical signs of acute thrombosis in the medical charts and confirmed by radiographic evidence </p> <p>‐ Database analysis</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matched</p> <p> </p> <p>‐ No cross‐over occurred.</p> <p> </p> <p>‐ 18 patients unmatched (25%) from the PCC group because of more complex surgical procedure </p> <p> </p> <p>‐ Clear selection bias in choosing which patients received PCCs making it impossible to ascertain whether the complications observed were truly from the PCCs or the surgical complexity </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or clotting factor based therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unsure when intervention was given</p> <p>No mention of POC or lab tests</p> <p>No protocol</p> <p>The decision to give PCC was left up to the surgeon, anaesthetist, or intensivist</p> <p>Normal standard dose of PCC was 1500 units </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No reports of missing data.</p> <p> </p> <p>Collection of data ‐ from Austin hospital blood bank and cross‐referenced with the Australian Society of Cardiothoracic Surgeons database </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No mention of how they diagnosed thrombosis in patients</p> <p>‐ Clinical or radiological assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on absolute numbers and on matched pairs</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>CPB: Cardiopulmonary Bypass <br/>DVT: Deep Vein Thrombosis<br/>e‐CABG: electronic Coronary Artery Bypass Graft <br/>FFP: Fresh Frozen Plasma <br/>ICU: Intensive Care Unit <br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>PE: Pulmonary Embolism<br/>POC: Point Of Care <br/>rFVIIa: Recombinant Factor VIIa<br/>SMD: Standardised Mean Difference <br/>TXA: Tranexamic Acid <br/>vs: Versus </p> </div> </div> </section> <section id="CD013551-sec-0063"> <h5 class="title">Mortality</h5> <p>Two RCTs reported on mortality (<a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>; <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>).  There is no evidence from RCTs showing a difference in mortality with PCC compared to standard care (OR 0.53, 95% CI 0.12 to 2.35; participants = 151; studies = 2; moderate‐quality evidence; I<sup>2</sup> = 0%; <a href="./references#CD013551-fig-0023" title="">Analysis 1.9</a>). </p> <p>Six NRS (<a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a>; <a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>) reported on mortality data in a total of 1334 patients. PCC may have little to no effect on mortality compared to standard care but the evidence is very uncertain (OR 1.02, 95% CI 0.69 to 1.51; participants = 1334; studies = 6; very low‐quality evidence; I<sup>2</sup> = 0%; <a href="./references#CD013551-fig-0024" title="">Analysis 1.10</a>). Five studies presented propensity‐matched data (<a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>) with an OR 1.02 (95% CI 0.68 to 1.53; participants = 1164; studies = 5; I<sup>2</sup> = 0%; very low‐quality evidence). </p> <p>A sensitivity analysis that included <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>, provided an OR of 0.96 (95% CI 0.55 to 1.69, participants = 512; studies = 3). Sensitivity analysis looking at the inclusion of trials with matched and unmatched data showed no difference between both the matched and unmatched data finding that PCCs result in little to no difference in mortality. </p> <p>The risk of bias for the six NRSs were critical for two, serious for one and moderate for three studies; this is due to unmatched data, inclusion of non‐cardiopulmonary bypass patients, multiple analysis, not all patients able to be matched and exclusion of high risk patients due to no appropriate match (<a href="#CD013551-fig-0006">Figure 6</a>, <a href="#CD013551-tbl-0005">Table 3</a>). </p> <div class="table" id="CD013551-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for mortality</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No matching occurred</p> <p> </p> <p>‐ The PCC group had higher‐complexity surgery, duration and individual participant risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups are clearly defined. The groups received either PCC or FFP.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No mention of dose given</p> <p>‐ No mention of co‐interventions</p> <p>‐ No mention of usual clinical practice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assumed this was low because the authors have not mentioned any missing data. No mention on how authors collected their data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No multiple subgroup analysis. Reported on what their methods stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>No matching of groups</p> <p>PCC patients were of a higher‐risk group.</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ The intention of study was to review PCC vs FFP in patients undergoing cardiac surgery on CPB but they have included off‐CPB patients (FFP group 27% and PCC group 24%) </p> <p>‐ Propensity matching occurred (101 patients each group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC +/‐ FFP or FFP alone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised heparin, protamine and TXA protocol</p> <p>‐ Clinically appropriate dose of PCC and FFP</p> <p>‐ No agreed coagulation algorithm amongst the hospitals</p> <p>‐ There was no decision‐making process around when to give intervention or comparison.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Three patients had missing data on location of surgical bleeding</p> <p>‐ Collected data from e‐CABG registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No multiple subgroup analysis. Reported on what their methods stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity matching</p> <p>‐ Important domains were measured and accounted for</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coinciding for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ This was not a deviation from standard practice.</p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Use of extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two types of analyses were conducted.</p> <p>‐ Propensity score‐adjusted  and propensity score‐matched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ There was matching of patients in each intervention group.</p> <p>‐ 69 patients in PCC group could not be matched due to being a higher‐risk population (emergency surgery, longer CPB time and complex surgery) </p> <p>‐ Two variables were not able to be matched with a SMD &lt; 10% (CPB time and diabetes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs all given intraoperatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that PCC group were able to receive FFP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised care mentioned</p> <p>‐ Both groups received rFVIIa with no statistical significance between the groups.</p> <p>‐ POC testing and lab tests to guide transfusion requirements</p> <p>‐ PCCs were given according to a protocol.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 18 patients excluded due to missing data (8%)</p> <p>‐ Data was obtained from institutional databases.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 patients of higher complexity were not included in the study. We believe these patients would have provided objective evidence for the higher‐risk population group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Matching occurred with a control based on demographic and surgical characteristics.</p> <p>‐ 6/65 patients could not be matched.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>All PCCs and their 1:1:1 blood products given in OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined intervention group and comparison group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unclear dose of protamine/antifibrinolytics</p> <p>‐ If bleeding, they used a 1: 1:1: transfusion as per protocol.</p> <p>‐ Intervention used if ongoing bleeding despite transfusion; this was based on clinician judgement </p> <p>‐ Control group got standard therapy; intervention group got PCCs if they continued to bleed (potentially a higher‐risk population) </p> <p>‐ Unclear if they used POC testing or lab bloods</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Collection of data ‐ retrospective data base analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matched</p> <p> </p> <p>‐ No cross‐over occurred.</p> <p> </p> <p>‐ 18 patients unmatched (25%) from the PCC group because of more complex surgical procedure </p> <p> </p> <p>‐ Clear selection bias in choosing which patients received PCCs making it impossible to ascertain whether the complications observed were truly from the PCCs or the surgical complexity. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or clotting factor‐based therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unsure when intervention ws given.</p> <p>No mention of POC or lab tests</p> <p>No protocol</p> <p>The decision to give PCC was left up to the surgeon, anaesthetist, or intensivist.</p> <p>Normal standard dose of PCC was 1500 units </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No reports of missing data.</p> <p> </p> <p>Collection of data ‐ from Austin hospital blood bank and cross‐referenced with the Australian Society of Cardiothoracic Surgeons database </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on absolute numbers and matched pairs </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>CPB: Cardiopulmonary Bypass <br/>e‐CABG: electronic Coronary Artery Bypass Graft<br/>FFP: Fresh Frozen Plasma <br/>ICU: Intensive Care Unit <br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>POC: Point Of Care <br/>rFVIIa: Recombinant Factor VIIa<br/>SMD: Standardised Mean Difference <br/>TXA: Tranexamic Acid  </p> </div> </div> </section> <section id="CD013551-sec-0064"> <h5 class="title">Bleeding</h5> <p>Two RCTs reported on chest drain output; <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> recorded 24‐hour chest drainage while <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> recorded both 12 and 24 hours of chest drainage.  PCCs may result in little to no difference in chest drain output (MD = ‐107; 95% CI ‐78 to 65; participants = 151; studies = 2; low‐quality evidence; I<sup>2</sup> = 66%; <a href="./references#CD013551-fig-0026" title="">Analysis 1.12</a>). </p> <p>No NRS studies reported chest drain output in the first 12 hours.  </p> </section> <section id="CD013551-sec-0065"> <h5 class="title">Intensive care unit length of stay</h5> <p>Two RCTs reported on ICU length of stay (<a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>; <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>).  PCC may have little to no effect on this outcome compared to standard care (MD = ‐0.35; 95% CI ‐19.26 to 18.57; participants = 151; studies = 2; moderate‐quality evidence; I<sup>2</sup> = 0%; <a href="./references#CD013551-fig-0027" title="">Analysis 1.13</a>). </p> <p>One NRS (<a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>) reported on this outcome with a total of 450 patients. PCCs may have little to no effect on intensive care length of stay comparative to standard care but the evidence is very uncertain (MD = ‐18.00; 95% CI ‐43.14 to 7.14; participants = 450; studies = 1; very low‐quality evidence; <a href="./references#CD013551-fig-0027" title="">Analysis 1.13</a>). </p> <p>The risk of bias for the one NRS was moderate; this is due to multiple analysis (<a href="#CD013551-fig-0007">Figure 7</a>, <a href="#CD013551-tbl-0006">Table 4</a>). </p> <div class="table" id="CD013551-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for ICU length of stay</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity matching</p> <p>‐ Important domains were measured and accounted for</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Use of extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two types of analysis:</p> <p>Propensity score‐adjusted and propensity score‐matched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>FFP: Fresh Frozen Plasma<br/>PCC: Prothrombin Complex Concentrate </p> </div> </div> </section> <section id="CD013551-sec-0066"> <h5 class="title">Incidence of renal replacement therapy </h5> <p>One RCT reported on renal replacement therapy (<a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>) which showed that PCCs may have little to no effect on this outcome (OR 0.72, 95% CI 0.14 to 3.59; participants = 50; studies = 1; low‐quality evidence; <a href="./references#CD013551-fig-0029" title="">Analysis 1.15</a>) </p> <p>Two NRSs (<a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>) reported on this outcome with a total of 684 patients. PCC may have little to no effect on the incidence of renal replacement therapy comparative to standard care but the evidence is very uncertain (OR 1.46, 95% CI 0.71 to 2.98; participants = 684; studies = 2; very low‐quality evidence; I<sup>2</sup> = 0%; <a href="./references#CD013551-fig-0030" title="">Analysis 1.16</a>). </p> <p>The risk of bias for the two NRSs was moderate; this is due to multiple analysis and not all patients were able to be matched leading to exclusion of high‐risk patients (<a href="#CD013551-fig-0008">Figure 8</a>, <a href="#CD013551-tbl-0007">Table 5</a>). </p> <div class="table" id="CD013551-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for renal replacement therapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity matching</p> <p>‐ Important domains were measured and accounted for</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ This was not a deviation from standard practice.</p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Use of extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two types of analysis: propensity score‐adjusted and propensity score‐matched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ There was matching for patients in each intervention group.</p> <p>‐ 69 patients in PCC group could not be matched due to being a higher‐risk population (emergency surgery, longer CPB time and complex surgery). </p> <p>‐ Two variables were not able to be matched with a SMD &lt;10% (CPB time and diabetes).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs all given intraoperatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that PCC group were able to receive FFP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised care mentioned</p> <p>‐ Both groups received rFVIIa with no statistical significance between the groups.</p> <p>‐ POC testing and lab tests to guide transfusion requirements</p> <p>‐ PCCs were given according to a protocol.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 18 patients excluded due to missing data (8%)</p> <p>‐ Data were obtained from institutional databases.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 69 patients of higher complexity were not included in the study. These patients would have provided objective evidence for the higher‐risk population group. </p> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>CPB: Cardiopulmonary Bypass<br/>PCC: Prothombin Complex Concentrate<br/>POC: Point of Care Testing<br/>rFVIIa: Recombinant Factor VIIa<br/>SMD: Standardisd Mean Difference </p> </div> </div> </section> <section id="CD013551-sec-0067"> <h5 class="title">Ventilator hours</h5> <p>One RCT reported on this outcome (<a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>) which showed that PCCs may have little to no effect on this outcome compared to standard treatment (MD ‐0.8; 95% CI ‐4.49 to 2.89; participants = 101; studies = 1; low‐quality evidence; <a href="./references#CD013551-fig-0031" title="">Analysis 1.17</a>). </p> <p>One NRS reported on this outcome (<a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>) with a total of 450 patients. PCC may have little to no effect on the number of hours spent on a ventilator comparative to standard care but the evidence is very uncertain (MD ‐5.20; 95% CI ‐23.10 to 12.70; participants = 450; studies = 1; very low‐quality evidence; <a href="./references#CD013551-fig-0032" title="">Analysis 1.18</a>). </p> <p>The risk of bias for the one NRS was moderate; this is due to multiple analysis (<a href="#CD013551-fig-0009">Figure 9</a>, <a href="#CD013551-tbl-0008">Table 6</a>). </p> <div class="table" id="CD013551-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for ventilator hours</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity matching</p> <p>‐ Important domains were measured and accounted for.</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coinciding for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ This was not a deviation from standard practice.</p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Use of extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>Propensity score‐adjusted and propensity score‐matched pairs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>FFP: Fresh Frozen Plasma<br/>PCC: Prothrombin Complex Concentrate<br/>POC: Point of Care </p> </div> </div> </section> <section id="CD013551-sec-0068"> <h5 class="title">Adverse events</h5> <p>One RCT <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> reported on other adverse events. Adverse events were reported for both PCC and FFP groups; most of these are likely to be related to the surgery and postoperative course, such as chest pain, malaise, pleuritic pain and pulseless electrical activity. Both groups had similar numbers of adverse events.   </p> <p>No NRS reported on additional adverse outcomes.  One study reported on fluid overload (<a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a>); however, the authors did not define how they diagnosed fluid overload and so this is not included as a true adverse event. </p> </section> </section> <section id="CD013551-sec-0069"> <h4 class="title">2. PCC versus rFVIIa</h4> <p>There were no RCTs evaluating the use of this comparison.  </p> <section id="CD013551-sec-0070"> <h5 class="title">Blood products transfused</h5> <p>We identified two NRS studies that reported on red cell transfusion (<a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>; <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>). PCC likely results in a large reduction in the number of RBCs transfused intraoperatively in comparison to rFVIIa (MD ‐4.98, 95% CI ‐6.37 to ‐3.59; participants = 256; studies = 2; moderate‐quality evidence; I<sup>2</sup> = 0%; <a href="./references#CD013551-fig-0033" title="">Analysis 2.1</a>). <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> also provided postoperative red cell transfusion. PCC may have little to no effect on the number of blood units transfused postoperatively comparative to rFVIIa but the evidence is very uncertain (MD ‐1.06; 95% CI ‐2.48 to 0.36; participants = 106; studies = 1; very low‐quality evidence; <a href="./references#CD013551-fig-0033" title="">Analysis 2.1</a>). </p> <p>One study mentioned incidence of red cell transfusions (<a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>). PCC may have little to no effect on the incidence of RBCs transfused compared to rFVIIa but the evidence is very uncertain (OR 0.16; 95% CI 0.02 to 1.56; participants = 150; studies = 1; very low‐quality evidence; <a href="./references#CD013551-fig-0034" title="">Analysis 2.2</a>). </p> <p>We were unable to conduct a sensitivity analysis on either of these outcomes due to having no studies with moderate or lower risk of bias. We were unable to conduct subgroup analysis on 3‐ versus 4‐factors and adult versus child due to the lack of studies.  </p> <p>The risk of bias for the two NRSs was serious for one and critical for one study; this is due to a disproportionately high dose of rFVIIa and not being adequately matched (<a href="#CD013551-fig-0010">Figure 10</a>, <a href="#CD013551-tbl-0009">Table 7</a>). </p> <div class="table" id="CD013551-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for blood products (RBC) transfused</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matching occurred for all baseline characteristics except EGFR and procedure type. </p> <p> </p> <p>‐ Procedure type appeared to be more complex in the PCC group.</p> <p> </p> <p>‐ 5 of the remaining 58 were then excluded due to inability to be matched with rFVIIa group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>Both PCCs and FVIIa were given in OR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that they analysed patients receiving PCCs or rFVIIa. No definition of what constituted refractory bleeding and initiation of interventions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ rFVIIa group received 90 mcg/kg and PCC group received 27 IU/kg (median).</p> <p> </p> <p>‐ The rFVIIa dose exceeded recognised and accepted doses for rFVIIa.</p> <p>‐ No definition of when patients received intervention</p> <p>‐ This was a safety study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 14/72 patients had incomplete data therefore were excluded.</p> <p> </p> <p>Data were collected via an electronic medical record database that was retrospectively queried. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as described in their methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> High rFVIIa dose exceeding common recommended practice</p> <p> </p> <p>‐ Uncertainty around increased cell salvage and product administration in the rFVIIa group. This could be result of clinician bias or a higher risk population. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Matched on age, sex and CPB duration</p> <p> </p> <p>‐ Other factors unmatched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 40% of patients received rFVIIa in ICU.</p> <p>‐ 100% of patients received PCCs in theatre.</p> <p>Follow‐up may have started before intervention.</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Followed institutional protocol</p> <p> </p> <p>‐ Cross‐over of patients in PCC group (24% patients in the PCC group also received rVIIa). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data</p> <p> </p> <p>Collection of data not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group.</p> <p>‐ Objective outcomes</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Editorial, not a published paper</p> <p> </p> <p>‐ Comparable doses</p> <p> </p> <p>‐ Not propensity matched</p> <p> </p> <p>‐ Issues with initiation of intervention (theatre vs ICU)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CPB: Cardiopulmonary Bypass<br/>EGFR: Estimated Glomerular Filtration Rate<br/>ICU: Intensive Care Unit<br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>rFVIIa: Recombinant Factor VIIa </p> </div> </div> </section> <section id="CD013551-sec-0071"> <h5 class="title">Thrombotic events</h5> <p>Four studies (<a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a>; <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>; <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>; <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>) reported on the incidence of thrombosis. <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> reported zero events in both study arms, therefore, did not contribute to the meta‐analysis leaving a total of 257 patients. PCC may have little to no effect on the number of thrombotic events comparative to rFVIIa but the evidence is very uncertain (OR 0.51, 95% CI 0.23 to 1.16; participants = 257; studies = 3; very low‐quality evidence; I<sup>2</sup> = 0%; <a href="./references#CD013551-fig-0035" title="">Analysis 2.3</a>). </p> <p>Sensitivity analysis looking at the inclusion of trials with matched and unmatched data showed no difference, finding that PCC results in little to no difference in thrombotic events. One study presented matched data (<a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>), with an OR of 0.50 (95% CI 0.19 to 1.30; participants = 106; studies = 1; very low‐quality evidence). </p> <p>One study (<a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>) did not have any thrombotic events in either group. We were unable to perform a sensitivity analysis due to having no studies with moderate or low risk of bias. We were unable to do subgroup analysis on 3‐ and 4‐factors versus rFVIIa and on adults versus children due to a lack of studies.  </p> <p>The risk of bias for the three NRSs were critical for two and serious for one study. This is due to no matching and a disproportionately high dose of rFVIIa (<a href="#CD013551-fig-0011">Figure 11</a>, <a href="#CD013551-tbl-0010">Table 8</a>). </p> <div class="table" id="CD013551-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for thrombotic events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Only 22 patients</p> <p>‐ No matching occurred</p> <p>‐ Patients received either PCC or rFVIIa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or rFVIIa.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unclear decision‐making process of clinicians treating patients with intervention</p> <p>No mention of POC or Lab tests</p> <p>‐ No mention of use of tranexamic acid and protamine</p> <p>‐ Increased FFP usage in the PCC group</p> <p>‐ Mild dose of rFVIIa (32 mcg/kg) compared with PCC (20 IU/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Chart review from paper and electronic documentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group.</p> <p>‐ Did not mention how they detected thrombosis and thrombotic events (i.e. clinically or radiological assessment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on what their methods stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>‐ No matching </p> <p>‐ Small sample size </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matching occurred for all baseline characteristics except EGFR and procedure type. </p> <p> </p> <p>‐ Procedure type appeared to be more complex in the PCC group.</p> <p> </p> <p>‐ 5 of the remaining 58 were then excluded due to inability to be matched with rFVIIa group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>Both PCCs and FVIIa were given in OR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that they analysed patients receiving PCCs or rFVIIa. No definition of what constituted refractory bleeding and initiation of interventions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ rFVIIa group received 90mcg/kg and PCC group received 27 IU/kg (median).</p> <p> </p> <p>‐ The rFVIIa dose exceeded recognised and accepted doses for rFVIIa.</p> <p>‐ No definition of when patients received intervention</p> <p>‐ This was a safety study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 14/72 patients had incomplete data therefore were excluded.</p> <p> </p> <p>Data were collected via an electronic medical record database that was retrospectively queried. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ CVA defined as new postoperative stroke being documented by a neurologist in the electronic medical record or on autopsy </p> <p>‐ DVT defined as postoperative ultrasound diagnosing acute DVT</p> <p>‐ PE defined as CT or autopsy demonstrating acute PE</p> <p>‐ MI defined as new native coronary artery or coronary artery bypass graft occlusion demonstrated on postoperative cardiac catheterisation or wall motion abnormalities seen on echocardiogram that resolved with PCI or CABG </p> <p>‐ All new intracardiac thrombus as noted on postoperative echo or autopsy </p> <p>Electronic medical record retrospectively queried</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High rFVIIa dose exceeding common recommended practice</p> <p> </p> <p>Matched for most of baseline variables</p> <p> </p> <p>‐ Uncertainty around increased cell salvage and product administration in the rFVIIa group. This could be result of clinician bias or a higher‐risk population. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No propensity matching occurred.</p> <p> </p> <p>‐ Two groups had baseline differences in haemoglobin concentration and haematocrit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> <p>Unclear in the study when given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or rFVIIa alone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No mention of coagulation studies or coagulation algorithm</p> <p>‐ Decision to give intervention was based on clinical judgement.</p> <p>‐ High rFVIIa dose</p> <p>‐ Intervention not comparable due to differences in doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data</p> <p> </p> <p>Collection of data ‐ electronic health record system</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group.</p> <p>‐ No mention of how they diagnosed thrombosis in patients: clinical or radiological assessment </p> <p> </p> <p>Collected data from electronic medical record system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Not matched</p> <p> </p> <p>‐ High dose of rFVIIa dose (decided by surgeons) that was higher than most institutions standard practice ‐ 66 mcg/kg </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Matched on age, sex and CPB duration</p> <p> </p> <p>‐ Other factors unmatched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 40% of patients received rFVIIa in ICU.</p> <p>‐ 100% of patients received PCCs in theatre.</p> <p>‐ Follow‐up may have started before intervention.</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Followed institutional protocol</p> <p> </p> <p>‐ Cross‐over of patients in PCC group (24% patients in the PCC group also received rVIIa). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data</p> <p> </p> <p>Collection of data not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group.</p> <p> </p> <p>No mention of how they diagnosed thrombosis in patients: clinical or radiological assessment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>‐ Comparable doses</p> <p> </p> <p>‐ Not matched</p> <p> </p> <p>‐ Issues with initiation of intervention (theatre vs ICU)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CABG: Coronary Artery Bypass Graft Surgery<br/>CPB: Cardiopulmonary Bypass<br/>CT: Computed Tomography<br/>CVA: Cerebrovascular Accident<br/>DVT: Deept Vein Thrombosis<br/>EGFR: Estimated Glomerular Filtration Rate<br/>FFP: Fresh Frozen Plasma<br/>ICU: Intensive Care Unit<br/>MI: Myocardial Infarction<br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>PCI: Percutaneous Coronary Intervention<br/>PE: Pulmonary Embolism<br/>POC: Point Of Care <br/>rFVIIa: Recombinant Factor VIIa </p> </div> </div> <p><b>Mortality</b> </p> <p>We included three studies (<a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a>; <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>; <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>) that reported on mortality. </p> <p>PCC may have little to no effect on the incidence of mortality comparative to rFVIIa but the evidence is very uncertain (OR 1.07, 95% CI 0.38 to 3.03; participants = 278; studies = 3; very low‐quality evidence; I<sup>2</sup> = 40%; <a href="./references#CD013551-fig-0036" title="">Analysis 2.4</a>). </p> <p>Sensitivity analysis looking at the inclusion of trials with matched and unmatched data showed no difference between groups finding that PCCs have little to no difference on mortality. One study presented matched data (<a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>) with an OR of 0.84 (95% CI 0.26 to 2.69; participants =106; studies = 1; very low‐quality evidence). </p> <p>We were unable to perform a sensitivity analysis as no studies had moderate or low risk of bias. </p> <p>The risk of bias for the three NRSs were critical for two and serious for one study. This is due to no matching and a disproportionately high dose of rFVIIa (<a href="#CD013551-fig-0012">Figure 12</a>, <a href="#CD013551-tbl-0011">Table 9</a>). </p> <div class="table" id="CD013551-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for mortality</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Only 22 patients</p> <p>‐ No matching occurred.</p> <p>‐ Patients received either PCC or rFVIIa.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or rFVIIa.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unclear decision‐making process of clinicians treating patients with intervention</p> <p>No mention of POC or Lab tests</p> <p>‐ No mention of use of tranexamic acid and protamine</p> <p>‐ Increased FFP usage in the PCC group</p> <p>‐ Mild dose of rFVIIa (32 mcg/kg) compared with PCC (20 IU/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data</p> <p>Chart review from paper and electronic documentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on what their methods stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>‐ No matching of groups</p> <p> </p> <p>‐ Small sample size may have contributed to analysing outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matching occurred for all baseline characteristics except EGFR and procedure type. </p> <p> </p> <p>‐ Procedure type appeared to be more complex in the PCC group.</p> <p> </p> <p>‐ 5 of the remaining 58 were then excluded due to inability to be matched with rFVIIa group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coinciding for all participants.</p> <p>Both PCCs and FVIIa were given in OR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that they analysed patients receiving PCCs or rFVIIa. No definition of what constituted refractory bleeding and initiation of interventions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ rFVIIa group received 90 mcg/kg and PCC group received 27 IU/kg (median).</p> <p> </p> <p>‐ The rFVIIa dose exceeded recognised and accepted doses for rFVIIa.</p> <p>‐ No definition of when patients received intervention</p> <p>‐ This was a safety study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 14/72 patients had incomplete data, therefore were excluded.</p> <p> </p> <p>Data were collected via an electronic medical record database that was retrospectively queried. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High rFVIIa dose exceeding common recommended practice</p> <p> </p> <p>Matched for most of baseline variables </p> <p> </p> <p>Uncertainty around increased cell salvage and product administration in the rFVIIa group This could be a higher‐risk population. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Matched on age, sex and CPB duration</p> <p> </p> <p>‐ Other factors unmatched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 40% of patients received rFVIIa in ICU.</p> <p>‐ 100% of patients received PCCs in theatre.</p> <p>Follow‐up may have started before intervention.</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Followed institutional protocol</p> <p> </p> <p>‐ Cross‐over of patients in PCC group (24% patients in the PCC group also received rVIIa). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data</p> <p> </p> <p>Collection of data not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>Comparable doses</p> <p> </p> <p>Not matched</p> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CPB: Cardiopulmonary Bypass<br/>EGFR: Estimated Glomerular Filtration Rate<br/>FFP: Fresh Frozen Plasma<br/>ICU: Intensive Care Unit<br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>POC: Point Of Care<br/>rFVIIa: Recombinant Factor VIIa </p> </div> </div> </section> <section id="CD013551-sec-0072"> <h5 class="title">Bleeding</h5> <p>One study (<a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>) reported on 12‐hour chest drain output with a total of 150 patients. PCC may reduce bleeding comparative to rFVIIa but the evidence is very uncertain (MD ‐674.34; 95% CI ‐906.04 to ‐442.64; participants = 150; studies = 1; very low‐quality evidence; <a href="./references#CD013551-fig-0037" title="">Analysis 2.5</a>). </p> <p>We were unable to conduct any sensitivity or subgroup analysis due to a lack of studies.</p> <p>The risk of bias for the one NRS was critical. This was due to inadequate matching. </p> </section> <section id="CD013551-sec-0073"> <h5 class="title">Intensive care unit length of stay</h5> <p>One study (<a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>) reported on this outcome with a total of 106 patients. PCC may have little to no effect on intensive care length of stay comparative to rFVIIa but the evidence is very uncertain (MD ‐40.00; 95% CI ‐110.41 to 30.41; participants = 106; studies = 1; very low‐quality evidence; <a href="./references#CD013551-fig-0038" title="">Analysis 2.6</a>). </p> <p>We were unable to conduct any sensitivity or subgroup analysis due to a lack of studies.</p> <p>The risk of bias for the one NRS was serious. This was due to a disproportionately high dose of rFVIIa (<a href="#CD013551-fig-0013">Figure 13</a>, <a href="#CD013551-tbl-0012">Table 10</a>). </p> <div class="table" id="CD013551-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for ICU length of stay</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matching occurred for all baseline characteristics except EGFR and procedure type </p> <p> </p> <p>‐ Procedure type appeared to be more complex in the PCC group</p> <p> </p> <p>‐ 5 of the remaining 58 were then excluded due to inability to be matched with rFVIIa group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>Both PCCs and FVIIa were given in OR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that they analysed patients receiving PCCs or rFVIIa. No definition of what constituted refractory bleeding and initiation of interventions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ rFVIIa group received 90 mcg/kg and PCC group received 27 IU/kg (median).</p> <p> </p> <p>‐ The rFVIIa dose exceeded recognised and accepted doses for rFVIIa.</p> <p>‐ No definition of when patients received intervention</p> <p>‐ This was a safety study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 14/72 patients had incomplete data, therefore were excluded.</p> <p> </p> <p>Data were collected via an electronic medical record database that was retrospectively queried. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High rFVIIa dose exceeding common recommended practice</p> <p> </p> <p>Matched for most of baseline variables </p> <p> </p> <p>Increased cell salvage and product administration in the rFVIIa group This could be a higher‐risk population. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EGFR: Estimated Glomerular Filtration Rate<br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>rFVIIa: Recombinant Factor VIIa </p> </div> </div> </section> <section id="CD013551-sec-0074"> <h5 class="title">Incidence of renal impairment</h5> <p>One study (<a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>) reported on acute renal impairment with a total of 106 patients. PCC may reduce the incidence of renal impairment comparative to rFVIIa but the evidence is very uncertain (OR 0.29; 95% CI 0.12 to 0.71; participants = 106; studies = 1; very low‐quality evidence; <a href="./references#CD013551-fig-0039" title="">Analysis 2.7</a>). </p> <p>The risk of bias for the one NRS was serious. This was due to a disproportionately high dose of rFVIIa (<a href="#CD013551-fig-0014">Figure 14</a>, <a href="#CD013551-tbl-0013">Table 11</a>). </p> <div class="table" id="CD013551-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; renal replacement therapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matching occurred for all baseline characteristics except EGFR and procedure type. </p> <p> </p> <p>‐ Procedure type appeared to be more complex in the PCC group.</p> <p> </p> <p>‐ 5 of the remaining 58 were then excluded due to inability to be matched with rFVIIa group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coinciding for all participants.</p> <p>Both PCCs and FVIIa were given in OR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that they analysed patients receiving PCCs or rFVIIa. No definition of what constituted refractory bleeding and initiation of interventions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ rFVIIa group received 90 mcg/kg and PCC group received 27 IU/kg (median).</p> <p> </p> <p>‐ The rFVIIa dose exceeded recognised and accepted doses for rFVIIa.</p> <p>‐ No definition of when patients received intervention</p> <p>‐ This was a safety study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 14/72 patients had incomplete data, therefore were excluded.</p> <p> </p> <p>Data was collected via an electronic medical record database that was retrospectively queried. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ High rFVIIa dose exceeding common recommended practice</p> <p> </p> <p>‐ Authors matched for most of baseline variables </p> <p> </p> <p>Increased cell salvage and product administration in the rFVIIa group </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EGFR: Estimated Glomerular Filtration Rate<br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>rFVIIa: Recombinant Factor VIIa </p> </div> </div> </section> <section id="CD013551-sec-0075"> <h5 class="title">Ventilator hours</h5> <p>No studies reported on time spent on a ventilator postoperatively in the intensive care unit. </p> </section> <section id="CD013551-sec-0076"> <h5 class="title">Adverse events</h5> <p>No studies reported on other adverse events.</p> </section> <section id="CD013551-sec-0077"> <h5 class="title">Paediatrics </h5> <p>In the three paediatric studies (<a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a>; <a href="./references#CD013551-bbs2-0016" title="RybkaMM , SamsonovaNN , KlimovichLG , RogalskayaEA , KhichagovDY , TataryanFE . Correction of hemostasis with blood products in the surgical treatment of congenital heart disease in infants and young children. Anesteziologiia i Reanimatologiia2015;60(5):42-6. ">Rybka 2015</a>), doses ranged from 25 units/kg to 57 units/kg.  Further analysis could not be performed due to lack of paediatric studies. The paediatric studies all underwent high‐risk complex congenital surgery and none showed an increased risk of thrombosis. </p> <p><a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> used a large dose of PCC 50 u/kg and <a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a> used a more standard dose of 25 u/kg. <a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a> was the only study to do prospective screening of thrombotic events with daily bedside echocardiography to check for intra‐cardiac thrombosis. The study showed no difference in thrombotic events. </p> <p><a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> had 59 participants, and the outcomes also showed similar death and thrombosis risk, with decreased hospital length of stay and blood products used. These paediatric patients were highly representative of the paediatric cardiac surgical population; although these results are very encouraging with respect to the safe use of PCC, we need studies with a larger population.    </p> </section> <section id="CD013551-sec-0078"> <h5 class="title">Case Study</h5> <p>We identified only one catastrophic thrombotic event related to PCC administration in a case report (<a href="./references#CD013551-bbs2-0014" title="KosterA , Meyer-JarkT , SchirmerU , SandicaE . Fulminant intraoperative right heart and pulmonary artery thrombosis following prothrombin complex concentrate infusion after complex open heart surgery with cardiopulmonary bypass. A and A Case Reports2014;2(8):89-91. ">Koster 2014</a>). This should be interpreted with caution as the 22 year old congenital heart disease patient experiencing the event appeared to have underlying prothrombotic diathesis; this participant developed near complete thrombotic obstruction in their 12 year old tricuspid and pulmonic mechanical valves, despite been compliant with warfarin with a therapeutic INR at the time. Following cardiac surgery to correct these thrombotic obstructions, the participant was given PCC; during the infusion of 22 units/kg, a large thrombus formed.  </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013551-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013551-sec-0079"></div> <section id="CD013551-sec-0080"> <h3 class="title" id="CD013551-sec-0080">Summary of main results</h3> <p>Overall, we had a total of 18 studies (2 RCTs, 16 NRSs) that included 4993 patients. There were 4842 patients studied in the NRSs with 1986 patients having matched data. </p> <section id="CD013551-sec-0081"> <h4 class="title">PCC vs standard treatment</h4> <p>We found that PCCs were likely to reduce units of RBC transfusion in patients receiving PCCs. This was supported by moderate‐quality evidence from RCTs and by very low‐quality evidence from NRSs. We found that PCCs may reduce the incidence of RBC transfusion in patients receiving PCCs. This was supported by low‐quality evidence from an RCT and by low‐quality evidence from NRSs. </p> <p>PCCs may result in little to no difference in the incidence of postoperative bleeding, thrombotic events, mortality, intensive care length of stay, and incidence of renal replacement therapy when compared to standard therapy. This is supported by moderate‐ and low‐quality evidence from the RCTs and low‐quality evidence from the NRSs.   </p> </section> <section id="CD013551-sec-0082"> <h4 class="title">PCCs vs rFVIIa</h4> <p>The evidence suggests that PCCs results in a large reduction in total RBC units transfused when compared to rFVIIa. Intraoperative RBC unit transfusion may result in a reduction of up to five units. The quality of this evidence was considered to be moderate. </p> <p>PCCs may have little to no effect on thrombotic events, mortality, postoperative chest drain output, ICU length of stay and incidence of renal replacement therapy when compared to rFVIIa.  We determined that the quality of evidence for these outcomes was very low.   </p> </section> </section> <section id="CD013551-sec-0083"> <h3 class="title" id="CD013551-sec-0083">Overall completeness and applicability of evidence</h3> <p>Our review method identified 18 studies (2 RCTs, 16 NRSs) with 4993 total participants. All the studies were patients undergoing cardiac surgery. Fifteen studies (including the two RCTs) were in adult patients and three were in paediatric patients. </p> <section id="CD013551-sec-0084"> <h4 class="title">Target study population</h4> <p>All but one study described the type of cardiac surgery analysed. The participants were representative of the general cardiac surgical population, however, not all the patients included in these studies were categorised as requiring high‐risk cardiac surgery which we believe is the target population.   </p> <p>Our major concern was that high‐risk cardiac surgery was poorly represented in the published studies comparing PCCs to standard therapy. The group of patients that are likely to benefit from PCCs are those undergoing high‐risk cardiac surgery. These are the patients that become factor deficient, need early and rapid correction of their coagulopathy and can often not tolerate the volume associated with adequate FFP factor replacement. We appreciate there are many other patients' risk factors to take into account when addressing coagulopathy, however, we were using high‐risk surgery as a major risk factor for coagulopathy.   </p> <p>Of the two RCTs, <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> excluded first‐time isolated coronary artery bypass grafts and first‐time isolated aortic valve replacement (excluding active endocarditis) which helps to exclude the low risk of coagulopathy population. However, <a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a> included 30% of patients who underwent a coronary artery bypass (CABG) procedure and were not on cardiopulmonary bypass (CPB). All other studies had cardiac surgical patients who underwent surgery on CPB.    </p> </section> <section id="CD013551-sec-0085"> <h4 class="title">Paediatrics </h4> <p>The paediatric study participants all underwent high‐risk complex congenital surgery and so were representative of the paediatric cardiac surgical population. We found that the dosing in the paediatric studies was higher than in the adult studies, with no increase in thrombotic events.  </p> </section> <section id="CD013551-sec-0086"> <h4 class="title">Timing of intervention</h4> <p>The timing of the intervention varied from either within the operating theatre (9 trials), intensive care and operating theatre (3 trials) or not described (6 trials). We didn't explore any outcome differences between these trials. Although this is what occurs clinically, the authors feel that factor deficiency should initially be replaced in theatre with guidance from point‐of‐care viscoelastic testing. However, ongoing refractory bleeding could occur in both the operating room or the ICU, therefore, in these studies it is appropriate to have the intervention starting in either location.  </p> </section> </section> <section id="CD013551-sec-0087"> <h3 class="title" id="CD013551-sec-0087">Quality of the evidence</h3> <p>We used GRADE to assess the quality of our evidence. Two pilot RCTs and 16 NRSs were included in our analysis. Please refer to our summary of finding tables (<a href="./full#CD013551-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013551-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD013551-sec-0088"> <h4 class="title">PCC vs standard treatment</h4> <p>The RCTs had moderate quality of evidence, however, where there was only one study looking at incidence of blood products transfused and incidence of renal impairment, the quality of evidence was low due to overall low participant numbers.   </p> <p>The NRSs had very low quality of evidence, except for incidence of RBC transfusion which was graded as low due to a high number of patients and a well‐defined and measured outcome. The key contributor to the low quality of evidence was the risk of bias. The review authors, using the Robins‐I tool (<a href="./references#CD013551-bbs2-0104" title="SterneJA , HernanMA , ReevesBC , SavovicJ , BerkmanND , ViswanathanM , et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.">Sterne 2016</a>), determined that two of the NRSs had critical risk of bias, one had serious, and five had moderate and they were downgraded accordingly. </p> <p>The low event rate may indicate that this review does not have enough power to detect a difference. The secondary outcomes had even lower event rates and sample sizes and, as a consequence, had large confidence intervals. </p> </section> <section id="CD013551-sec-0089"> <h4 class="title">PCC Vs rFVIIa </h4> <p>In our PCC vs rFVIIa cohort, we found that there were even lower numbers of patients in all our outcomes, with similar downgrades due to risk of bias. Our primary outcome of RBC transfusion had a moderate quality of evidence as a result of a large effect size which allowed the evidence level to be upgraded despite having only two studies. The remaining primary and secondary outcomes had very low quality of evidence due to a low event rate and high risk of bias. </p> <p>There were only two studies that compared RBC transfusion (<a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>, <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>). Harper had a comparatively much larger dose of rFVIIa, and a large difference in the amount of cell saver blood collected between the two groups. This could suggest that the rFVIIa group was a higher‐risk population group. Tanaka had equivalent doses of the intervention, however, there was a difference in whether they received the treatment in the operating room or in the ICU. These factors could affect the observed outcome difference.   </p> <p>We have included studies with a critical risk of bias as we believe the totality of the evidence should be included as this clinical question has limited studies and evidence.   </p> </section> </section> <section id="CD013551-sec-0090"> <h3 class="title" id="CD013551-sec-0090">Potential biases in the review process</h3> <p>We conducted a thorough search and reduced potential bias by having two review authors assess study eligibility, data extraction, analysis and assessment of risk of bias in the included studies. We included all studies that compared PCCs to either standard therapy or rFVIIa. We contacted all the authors of any study where we could not extract relevant data for our outcomes. This was to reduce potential bias and also strengthen the overall outcome.   </p> </section> <section id="CD013551-sec-0091"> <h3 class="title" id="CD013551-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>There are two other published systematic reviews by <a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a> and <a href="./references#CD013551-bbs2-0108" title="Van den BrinkDP , WirtzMR , NetoAS , SchöchlH , ViersenV , BinnekadeJ , et al. Effectiveness of prothrombin complex concentrate for the treatment of bleeding: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis2020;18(10):2457-67.">Van den Brink 2020</a>. <a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a> reviewed the evidence of PCCs compared to FFP in cardiac surgery and <a href="./references#CD013551-bbs2-0108" title="Van den BrinkDP , WirtzMR , NetoAS , SchöchlH , ViersenV , BinnekadeJ , et al. Effectiveness of prothrombin complex concentrate for the treatment of bleeding: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis2020;18(10):2457-67.">Van den Brink 2020</a> reviewed the evidence of PCCs in three main areas of bleeding including trauma, cardiac surgery and liver surgery. </p> <p>The main differences between this review and <a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a> is that we included studies that not only compared PCCs (with or without FFP) to FFP alone, but also PCC and rFVIIa. This is due to PCC being used in two ways clinically and in the literature, one as factor replacement instead of FFP and the other in refractory bleeding instead of the commonly used rFVIIa. We also included paediatric cardiac studies and conference abstracts and posters, both of which were excluded by <a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a>. <a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a> included <a href="./references#CD013551-bbs2-0091" title="OrtmannE , BesserMW , SharplesLD , GerrardC , BermanM , JenkinsDP , et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesthesia and Analgesia2015;121(1):26-33.">Ortmann 2015</a> which we did not include in our analysis. The review authors determined that the patients selected by <a href="./references#CD013551-bbs2-0091" title="OrtmannE , BesserMW , SharplesLD , GerrardC , BermanM , JenkinsDP , et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesthesia and Analgesia2015;121(1):26-33.">Ortmann 2015</a> had a higher than normal incidence of preoperative anticoagulation and a resultant significantly higher INR compared to the normal population. We had specifically excluded studies with preoperative anticoagulation as this is a significant confounder.   </p> <p><a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a> also included <a href="./references#CD013551-bbs2-0002" title="ArnekianV , CamousJ , FattalS , Rezaiguia-DelclauxS , NottinR , StephanF . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2012;15(3):382-9. ">Arnekian 2012</a> in their systematic review which we did include but could not meta‐analyse. <a href="./references#CD013551-bbs2-0002" title="ArnekianV , CamousJ , FattalS , Rezaiguia-DelclauxS , NottinR , StephanF . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2012;15(3):382-9. ">Arnekian 2012</a> had a discrepancy in the results between the text and the tables and, despite trying to contact these authors, we were unable to determine which data were correct. The paper also included three groups of PCC, FFP + PCC and FFP alone; however, 50% of the FFP alone group also received PCCs, therefore, there was large cross‐over and confounding.   </p> <p>The outcomes were similar between the two reviews for our comparator group of PCC versus standard treatment. <a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a> included 24‐hour chest drain output, re‐exploration for bleeding and stroke in their secondary outcomes. We expanded our outcomes to include all thrombotic events described and only the first 12 hours of chest drain output. We also reviewed additional outcomes of days in intensive care and total ventilator hours. </p> <p>Our results showed similarities following meta‐analysis. The RBC transfused (units and % of patients transfused), mortality outcomes, and incidence of renal replacement therapy showed no difference between the two comparators. The <a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a> stroke outcome was similar to our incidence of thrombosis. </p> <p><a href="./references#CD013551-bbs2-0108" title="Van den BrinkDP , WirtzMR , NetoAS , SchöchlH , ViersenV , BinnekadeJ , et al. Effectiveness of prothrombin complex concentrate for the treatment of bleeding: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis2020;18(10):2457-67.">Van den Brink 2020</a> did a generalised systematic review looking at three areas of bleeding and PCC use. Their meta‐analysis of PCC use in cardiac surgery included the same studies as in this Cochrane Review, however, we excluded <a href="./references#CD013551-bbs2-0091" title="OrtmannE , BesserMW , SharplesLD , GerrardC , BermanM , JenkinsDP , et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesthesia and Analgesia2015;121(1):26-33.">Ortmann 2015</a> and <a href="./references#CD013551-bbs2-0059" title="BradfordCD , StahovichMJ , DembitskyWP , AdamsonRM , EngelbertJJ , PerreiterAS . Safety of Prothombin Complex Concentrate to control excess bleeding during continuous flow LVAD insertion. American Society for Artificial Internal Organs Journal2015;61(5):509-13.">Bradford 2015</a> due to a high proportion of preoperative anticoagulation, specifically warfarin, which was an exclusion of this review. Like this review, they also excluded <a href="./references#CD013551-bbs2-0002" title="ArnekianV , CamousJ , FattalS , Rezaiguia-DelclauxS , NottinR , StephanF . Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interactive Cardiovascular and Thoracic Surgery2012;15(3):382-9. ">Arnekian 2012</a>. However, their review combined both comparators of PCCs, FFP and rFVIIa. They included both <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> and <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> that exclusively looked at rFVIIa use compared to PCCs and added this to their meta‐analysis. So their meta‐analysis combined both interventions, PCCs and rFVIIa, but did not explain or highlight this.  </p> <p>Our results also showed similar outcomes in the reduction in RBC utilisation and no significant difference in thromboembolic events and mortality. They also discussed the credibility of these results due to the large heterogeneity of the studies.   </p> <p>The most recent publication is a European consensus statement on the use of 4‐factor PCC for cardiac and non‐cardiac surgical patients (<a href="./references#CD013551-bbs2-0065" title="ErdoesG , KosterA , OrtmannE , MeestersMI , BolligerD , BaryshnikovaE , et al. A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients. Anaesthesia2021;76(3):381-92.">Erdoes 2021</a>). The authors concluded that, for cardiac surgery, the patients were at higher risk of thromboembolic events, therefore, an initial lower half dose of 12.5 IU/kg should be used, followed by a second dose, if microvascular bleeding persisted. They believed this to be a rational risk‐adjusted strategy. This recommendation was based on the systematic review by <a href="./references#CD013551-bbs2-0099" title="RomanM , BiancariF , AhmedAB , AgarwalS , HadjinikolaouL , Al-SarrafA , et al. Prothrombin complex concentrate in cardiac surgery: a systematic review and meta-analysis. Annals of Thoracic Surgery2019;107(4):1275-83.">Roman 2019</a> and the retrospective cohort analysis done by <a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>. The authors of this European consensus statement are members of the Scientific Subcommittee of Haemostasis and Transfusion in the European Association of Cardiothoracic Anaesthesiology. </p> <p>These most recent publications show just how topical and important this question is in cardiac surgery as many centres have adopted PCC use worldwide, but we are lacking answers to guide our safe and effective use.  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013551-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013551-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph for RCT studies: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD013551-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph for RCT studies: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary for RCT studies: review authors' judgements about each risk of bias item for each included study" data-id="CD013551-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary for RCT studies: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-04" target="_blank"><b></b></a></p> </div><img alt="NRS: Blood products transfused (RBC) % of patients " data-id="CD013551-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>NRS: Blood products transfused (RBC) % of patients </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-05" target="_blank"><b></b></a></p> </div><img alt="NRS: PCCs thrombotic events " data-id="CD013551-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-05.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>NRS: PCCs thrombotic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-05.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-06" target="_blank"><b></b></a></p> </div><img alt="NRS: PCCs mortality " data-id="CD013551-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-06.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>NRS: PCCs mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-06.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-07" target="_blank"><b></b></a></p> </div><img alt="NRS: PCCs ICU length of stay " data-id="CD013551-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-07.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>NRS: PCCs ICU length of stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-07.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-08" target="_blank"><b></b></a></p> </div><img alt="NRS: PCCs renal replacement therapy " data-id="CD013551-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-08.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>NRS: PCCs renal replacement therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-08.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-09" target="_blank"><b></b></a></p> </div><img alt="NRS: PCCS ventilator duration" data-id="CD013551-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-09.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>NRS: PCCS ventilator duration</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-09.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-10" target="_blank"><b></b></a></p> </div><img alt="NRS: Factor VIIa blood products transfused (RBC) % patients " data-id="CD013551-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-10.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>NRS: Factor VIIa blood products transfused (RBC) % patients </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-10.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-11" target="_blank"><b></b></a></p> </div><img alt="NRS: Factor VIIa thrombotic events " data-id="CD013551-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-11.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>NRS: Factor VIIa thrombotic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-11.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-12" target="_blank"><b></b></a></p> </div><img alt="NRS: Factor VIIa mortality " data-id="CD013551-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-12.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>NRS: Factor VIIa mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-12.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-13" target="_blank"><b></b></a></p> </div><img alt="NRS: Factor VIIa ICU length of stay " data-id="CD013551-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-13.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>NRS: Factor VIIa ICU length of stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-13.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-FIG-14" target="_blank"><b></b></a></p> </div><img alt="NRS: Factor VIIa renal replacement therapy " data-id="CD013551-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-14.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>NRS: Factor VIIa renal replacement therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-FIG-14.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 1: RCT: Blood products transfused (RBC) in units" data-id="CD013551-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 1: RCT: Blood products transfused (RBC) in units </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 2: NRS: Blood products transfused (RBC) in units" data-id="CD013551-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 2: NRS: Blood products transfused (RBC) in units </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 3: RCT: Blood products transfused (RBC) % of patients" data-id="CD013551-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 3: RCT: Blood products transfused (RBC) % of patients </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 4: NRS: Blood products transfused (RBC) % of patients" data-id="CD013551-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 4: NRS: Blood products transfused (RBC) % of patients </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 5: RCT: Thrombotic events" data-id="CD013551-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 5: RCT: Thrombotic events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 6: NRS: Thrombotic events" data-id="CD013551-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 6: NRS: Thrombotic events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 7: NRS: Thrombotic events matched data" data-id="CD013551-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 7: NRS: Thrombotic events matched data </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 8: NRS: Thrombotic events (3‐factor vs 4‐factor)" data-id="CD013551-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 8: NRS: Thrombotic events (3‐factor vs 4‐factor) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 9: RCT: Mortality (30‐day)" data-id="CD013551-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 9: RCT: Mortality (30‐day)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 10: NRS: Mortality (30‐day)" data-id="CD013551-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 10: NRS: Mortality (30‐day)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 11: NRS: Mortality (30‐day)" data-id="CD013551-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 11: NRS: Mortality (30‐day)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 12: RCT: Bleeding (chest drain output) in mLs for the first 12 hours" data-id="CD013551-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 12: RCT: Bleeding (chest drain output) in mLs for the first 12 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 13: RCT: Intensive care length of stay in hours" data-id="CD013551-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 13: RCT: Intensive care length of stay in hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 14: NRS: Intensive care length of stay in hours" data-id="CD013551-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 14: NRS: Intensive care length of stay in hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 15: RCT: Incidence of renal replacement therapy" data-id="CD013551-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 15: RCT: Incidence of renal replacement therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 16: NRS: Incidence of renal replacement therapy" data-id="CD013551-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 16: NRS: Incidence of renal replacement therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 17: RCT: Ventilator hours" data-id="CD013551-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 17: RCT: Ventilator hours</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PCC versus standard treatment, Outcome 18: NRS: Ventilator hours" data-id="CD013551-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: PCC versus standard treatment, Outcome 18: NRS: Ventilator hours</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PCC versus rFVIIa, Outcome 1: Blood products transfused (RBC) in units" data-id="CD013551-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: PCC versus rFVIIa, Outcome 1: Blood products transfused (RBC) in units</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PCC versus rFVIIa, Outcome 2: Blood products transfused (RBC) % of patients" data-id="CD013551-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: PCC versus rFVIIa, Outcome 2: Blood products transfused (RBC) % of patients</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PCC versus rFVIIa, Outcome 3: Thrombotic events" data-id="CD013551-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: PCC versus rFVIIa, Outcome 3: Thrombotic events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PCC versus rFVIIa, Outcome 4: Mortality (30‐day)" data-id="CD013551-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: PCC versus rFVIIa, Outcome 4: Mortality (30‐day)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PCC versus rFVIIa, Outcome 5: Bleeding (chest drain output) in mLs for the first 12 hours" data-id="CD013551-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: PCC versus rFVIIa, Outcome 5: Bleeding (chest drain output) in mLs for the first 12 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PCC versus rFVIIa, Outcome 6: Intensive care length of stay in hours" data-id="CD013551-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: PCC versus rFVIIa, Outcome 6: Intensive care length of stay in hours</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013551-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/urn:x-wiley:14651858:media:CD013551:CD013551-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: PCC versus rFVIIa, Outcome 7: Incidence of renal replacement therapy" data-id="CD013551-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_t/tCD013551-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: PCC versus rFVIIa, Outcome 7: Incidence of renal replacement therapy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/media/CDSR/CD013551/image_n/nCD013551-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013551-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">PCC compared to standard treatment for cardiac surgery for the treatment of non‐surgical bleeding</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PCC compared to standard treatment for cardiac surgery for the treatment of non‐surgical bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> cardiac surgery for the treatment of non‐surgical bleeding<br/><b>Setting:</b> hospital (intraoperative and postoperative)<br/><b>Intervention:</b> PCC<br/><b>Comparison:</b> standard treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PCC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood products transfused (RBC) in units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean RCT: Blood products transfused (RBC) in units was 3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD</p> <p>0.89 lower</p> <p>(1.78 lower to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two pilot RCTs <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>; reported blood components in units at 24 hours and <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> reported units within 24 hours of start of surgery.   </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean NRS: blood products transfused (RBC) in units was 5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 1.87 lower<br/>(2.53 lower to 1.20 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>551<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two observational studies described intraoperative red cell transfusion (<a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>). They described this in mLs of red cells transfused and converted to units by assuming an average of 250 mL of blood per unit. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Blood products transfused (RBC) % of patients</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>830 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>721 per 1000<br/>(494 to 872) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.53<br/>(0.20 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One RCT <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> reported on incidence of RBC transfusion. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>889 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>812 per 1000<br/>(706 to 887) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.54<br/>(0.30 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1046<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three observational studies described the incidence of a red cell transfusion (<a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a>). <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> reported avoidance of red cell transfusion. <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> had a greater number of the PCC group receiving red cell transfusion but this was not significant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Thrombotic events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>95 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>64 per 1000<br/>(20 to 194) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.68<br/>(0.20 to 2.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two pilot RCTs. <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> reported on many thrombotic events; we only included those of stroke as the other outcomes e.g. mesenteric artery thrombosis and spinal cord ischaemia are more likely related to other complex factors. <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> reported on stroke/TIA, atrial and vascular thrombosis.  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>68 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000<br/>(60 to 126) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.32<br/>(0.87 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1359<br/>(7 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a> reported on acute cerebral infarcts only. <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> reported on postoperative myocardial infarction and cerebral infarcts. <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> reported on cerebral infarcts and venous thromboembolism (deep vein thrombosis and pulmonary embolism). <a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a> and <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> did not define how they measured thrombosis. <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> measured both arterial and venous thrombosis. One study (<a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a>) reported 0 events for both PCC and standard care groups and therefore did not contribute to the meta‐analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Mortality (30‐day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>39 per 1000<br/>(9 to 151) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.53 (0.12 to 2.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two pilot RCTs reported on this (<a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a>; <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>); lost 4 to follow‐up at 30 days.  </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>83 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000<br/>(59 to 120) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.02<br/>(0.69 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1334<br/>(6 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup><sup>3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a>; <a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a>; <a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> described 30‐day mortality. <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a>; <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a>; <a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> reported on in‐hospital mortality with no time frame given. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Intensive care length of stay in hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean RCT intensive care length of stay in hours was 84</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD</p> <p>0.35 lower</p> <p>(19.26 lower to 18.57 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two pilot RCTs with <a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a> reporting on ICU or HDU stay in days and <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> median ICU stay in days.   </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean NRS intensive care length of stay in hours was 128</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 18.00 lower<br/>(43.14 lower to 7.14 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>450<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3  5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> reported on ICU length of stay with a mean of 110 hours (+/‐ 118) in the PCC group and a mean of 128 hours (+/‐ 152) in the standard treatment group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Incidence of renal impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>160 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>120 per 1000<br/>(30 to 482) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.72 (0.14 to 3.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One pilot RCT (<a href="./references#CD013551-bbs2-0009" title="GreenL , RobertsN , CooperJ , AgarwalS , BrunskillSJ , ChangI , et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). Anaesthesia2021;76(7):892-901. GreenL , RobertsN , CooperJ , FieldJ , GillR , KleinA , et al. A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY). Trials2019;20(1):684. GreenL , RobertsN , PlattonS , O'BrienB , AgarwalS , GillR , et al. Impact of prothrombin complex concentrate and fresh frozen plasma on correction of haemostatic abnormalities in bleeding patients undergoing cardiac surgery (PROPHESY trial results). Anaesthesia2021;76(7):997-1000. ">Green 2021</a>) reported on number of patients requiring haemodialysis. <a href="./references#CD013551-bbs2-0013" title="BartoszkoJ , CallumJ , KarkoutiK . The association of prothrombin complex concentrates with transfusion requirement and postoperative outcomes in cardiac surgery: a post-hoc analysis of the fibres randomized controlled trial. Transfusion2020;60:252A-3A. KarkoutiK , BartoszkoJ , GrewalD , BingleyC , ArmaliC , CarrollJ , et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. JAMA 2021;4(4):e213936. KarkoutiK , CallumJ . The fares study: a multicenter, randomized, active-control, pragmatic, phase 2 pilot study comparing prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):378. ">Karkouti 2021</a> combined both haemodialysis and acute kidney injury with a 2‐fold increase in creatinine.   </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>41 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/>(29 to 113) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.46<br/>(0.71 to 2.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>684<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> and <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> reported on renal impairment postoperatively. Overall incidence was low with 20 patients in the PCC group and 14 in the standard treatment group. <a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> used the RIFLE criteria to define acute kidney injury. <a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> used serum creatinine measured from before surgery to the highest creatinine concentration on postoperative days 1 or 2. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding (chest drain output) in mLs for the first 12 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean RCT: Bleeding (chest drain output) in mLs for the first 12 hours was</p> <p>552</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD</p> <p>107.05 lower</p> <p>(278.92 lower to 64.83 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for imprecision as number of participants &lt; 400 </p> <p><sup>2</sup>Downgraded two levels for risk of bias associated with lack of randomisation </p> <p><sup>3</sup>Downgraded one level for risk of bias </p> <p><sup>4</sup>Downgraded one level for imprecision as number of events were &lt; 400 </p> <p><sup>5</sup>Downgraded one level for indirectness as only one study which did not represent all potential participants </p> <p><sup>6</sup>Downgraded one level for inconsistency </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">PCC compared to standard treatment for cardiac surgery for the treatment of non‐surgical bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013551-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">PCC compared to FVIIa for cardiac surgery for the treatment of non‐surgical bleeding</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PCC compared to FVIIa for cardiac surgery for the treatment of non‐surgical bleeding</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> cardiac surgery for the treatment of non‐surgical bleeding<br/><b>Setting:</b> hospital (intraoperative and postoperative)<br/><b>Intervention:</b> PCC<br/><b>Comparison:</b> FVIIa </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with FVIIa</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with PCC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood products transfused (RBC) in units ‐ intraoperative</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood products transfused (RBC) in units ‐ intraoperative was 12</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.98 lower<br/>(6.37 lower to 3.59 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256<br/>(2 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 2 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> and <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> reported on intraoperative red cell transfusion. <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> used mLs of red cells transfused and we converted to units by assuming 250 mL per unit of red cells. Overall effect was clinically significant with a 5 unit of red cells difference in the PCC group. However, in both <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> and <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a>, the rFVIIa group may include higher risk cardiac surgical patients. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood products transfused (RBC) % of patients</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>990 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>941 per 1000<br/>(664 to 994) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.16<br/>(0.02 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2  5 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> reported on incidence of red cell transfusion in patients. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombotic events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/>(22 to 103) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.51<br/>(0.23 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>407<br/>(4 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three studies reported on incidence of postoperative thrombosis; <a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a>; <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a>; <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>. <a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a> reported this as all thromboembolic events but this was not defined. <a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> defined thromboembolism as new cerebral vascular events, deep vein thrombosis, pulmonary embolism, myocardial infarction or new intracardiac thrombus. In <a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a>, thromboembolic events defined as venous thromboembolism, arterial thromboembolism or pulmonary embolism that occurred at any time postoperatively.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (30‐day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>135 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000<br/>(56 to 320) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.07<br/>(0.38 to 3.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278<br/>(3 observational studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> and <a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> reported on 30‐day mortality. <a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a> reported on in‐hospital mortality. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding (chest drain output) in mLs for the first 12 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean bleeding (chest drain output) in mLs for the first 12 hours was 1398</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 674.34 lower<br/>(906.04 lower to 442.64 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> was the only study that reported on 12‐hour chest drain output with a mean of 723.33 mL (+/‐ 442.78) in the PCC group and mean of 1397.67 mL (+/‐ 1002.69) in the rFVIIa group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive care length of stay in hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean intensive care length of stay in hours was 196</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 40 lower<br/>(110.41 lower to 30.41 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> was the only study that reported on ICU length of stay with a mean of 156 hours (+/‐ 155.46) in the PCC group and a mean of 196 hours (+/‐ 210.32) in the rFVIIa group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incidence of renal impairment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> <p>415 per 1000</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000<br/>(78 to 335) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.29<br/>(0.12 to 0.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(1 observational study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 5 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> reported on new acute kidney injury by the incidence of patients requiring postoperative dialysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the studies measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded two levels for risk of bias associated with lack of randomisation  </p> <p><sup>2</sup>Downgraded one level for risk of bias </p> <p><sup>3</sup>Downgraded one level for precision as number of participants &lt; 400 </p> <p><sup>4</sup>Upgraded two levels due to very large effect size </p> <p><sup>5</sup>Downgraded one level for precision as number of events were &lt; 400 </p> <p><sup>6</sup>Downgraded one level for indirectness as only one study which did not represent all potential participants </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">PCC compared to FVIIa for cardiac surgery for the treatment of non‐surgical bleeding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for blood products (RBC) transfused</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intention of study was to review PCC vs FFP in patients undergoing cardiac surgery for CPB but they have included off‐CPB patients (FFP group 27% and PCC group 24%). </p> <p>‐ Propensity‐matching occurred (101 patients each group).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC +/‐ FFP or FFP alone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised heparin, protamine and TXA protocol</p> <p>‐ Clinically appropriate dose of PCC and FFP</p> <p>‐ No agreed coagulation algorithm amongst the hospitals</p> <p>‐ There was no decision‐making process around when to give intervention or comparison.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>Collected data from e‐CABG registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No multiple subgroup analysis. Reported on what their methods stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Critical bias in domain 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity‐matching</p> <p>‐ Important domains were measured and accounted for</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ This was not a deviation from standard practice.</p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Use of extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two types of analyses were conducted with differing results. For RBC transfused they used: propensity score‐matched pairs and propensity score‐adjusted.  </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p> </p> <p> </p> <p>‐ Unclear if 57 patients who received both interventions were included in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ There were matching patients in each intervention group</p> <p>‐ 69 patients in PCC group could not be matched due to being a higher‐risk population (emergency surgery, longer CPB time and complex surgery). </p> <p>‐ Two variables were not able to be matched with a SMD &lt; 10% (CPB time and diabetes).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs were all given intraoperatively and not in ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that PCC group were able to receive FFP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised care mentioned</p> <p>‐ Both groups received rFVIIa with no statistical significance between the groups.</p> <p>‐ POC testing and lab tests to guide transfusion requirements</p> <p>‐ PCCs were given according to a protocol.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 18 patients excluded due to missing data (8%)</p> <p>‐ Data were obtained from institutional databases.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on what their methods stated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unfortunate to not have 69 patients of higher complexity included in the study. We believe these patients would have provided objective evidence for the higher‐risk population group. </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity‐matched</p> <p> </p> <p>‐ No cross‐over occurred.</p> <p> </p> <p>‐ 18 patients unmatched (25%) from the PCC group because of more complex surgical procedure </p> <p> </p> <p>‐ Clear selection bias in choosing which patients received PCCs making it impossible to ascertain whether the complications observed were truly from the PCCs or the surgical complexity </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or clotting factor‐based therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unsure when intervention was given</p> <p>No mention of POC or lab tests</p> <p>No protocol</p> <p>The decision to give PCC was left up to the surgeon, anaesthetist, or intensivist</p> <p>Median dose of PCC 1500 units </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No reports of missing data.</p> <p> </p> <p>Collection of data ‐ from Austin hospital blood bank and cross‐referenced with the Australian Society of Cardiothoracic Surgeons database </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assessors were aware of the intervention group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity‐matched pairs were evaluated by a multivariate logistic regression model adjusted for age, sex, total units of RBC, cryoprecipitate, FFP and platelets combined. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p> </p> <p>‐ Unclear as to timing of interventions</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>CPB: Cardiopulmonary Bypass <br/>e‐CABG: electronic Coronary Artery Bypass Graft <br/>FFP: Fresh Frozen Plasma <br/>ICU: Intensive Care Unit <br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>POC: Point Of Care <br/>SMD: Standard Mean Difference <br/>TXA: Tranexamic Acid  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for blood products (RBC) transfused</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for thrombotic events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No matching occurred.</p> <p> </p> <p>‐ The PCC group had higher‐complexity surgery, duration and individual participant risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU, follow‐up may have started before intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No mention of dose given</p> <p>‐ No mention of co‐interventions</p> <p>‐ No mention of usual clinical practice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assumed this was low because the authors have not mentioned any missing data. No mention of how authors collected their data. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group</p> <p>‐ Objective outcomes</p> <p>‐ Did not mention how they detected thrombosis and thrombotic events (i.e. clinically or radiological assessment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No multiple subgroup analysis Reported on what their methods stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>PCC patients were in a higher‐risk group</p> <p>No mention of doses, clinical practice and standard care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ The intention of study was to review PCC vs FFP in patients undergoing cardiac surgery on CPB but they have included off‐CPB patients (FFP group 27% and PCC group 24%) </p> <p>‐ Propensity matching occurred (101 patients each group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC +/‐ FFP or FFP alone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised heparin, protamine and TXA protocol</p> <p>‐ Clinically appropriate dose of PCC and FFP</p> <p>‐ No agreed coagulation algorithm amongst the hospitals</p> <p>‐ There was no decision‐making process around when to give intervention or comparison.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Three patients had missing data on the location of surgical bleeding</p> <p>‐ Collected data from e‐CABG registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective, assessors aware of intervention group</p> <p>‐ Objective outcomes</p> <p>‐ Discussed incidence of stroke but no mention how this was diagnosed (i.e. clinical or radiological) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No multiple subgroup analysis Reported on what their methods stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Critical bias in domain 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity matching</p> <p>‐ Important domains were measured and accounted for</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ This was not a deviation from standard practice.</p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group</p> <p>‐ Objective outcomes</p> <p>‐ Discussed incidence of stroke but no mention how this was diagnosed (i.e. clinical or radiological) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two types of analyses were conducted:</p> <p>propensity‐score adjusted and  propensity score‐matched </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>‐ Unclear if 57 patients who received both interventions were included in either group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ There was matching of patients in each intervention group</p> <p>‐ 69 patients in PCC group could not be matched due to being a higher‐risk population (emergency surgery, longer CPB time and complex surgery) </p> <p>‐ Two variables were not able to be matched with a SMD &lt; 10% (CPB time and diabetes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coinciding for all participants.</p> <p>PCCs all given intraoperatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that PCC group participants were able to receive FFP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised care mentioned</p> <p>‐ Both groups received rFVIIa with no statistical significance between the groups.</p> <p>‐ POC testing and lab tests to guide transfusion requirements</p> <p>‐ PCCs were given according to a protocol.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 18 patients excluded due to missing data (8%)</p> <p>‐ Data were obtained from institutional databases.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group</p> <p>‐ Objective outcomes</p> <p>Defined how they diagnosed stroke (clinically) and DVT/PE (radiological confirmation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unfortunate to not have 69 patients of higher complexity included in the study. We believe these patients would have provided objective evidence for the higher risk population group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0008" title="GiorniC , RicciZ , IodiceF , GaristoC , FaviaI , PolitoA , et al. Use of confidex to control perioperative bleeding in pediatric heart surgery: prospective cohort study. Paediatric Cardiology2013;35(2):208-14. ">Giorni 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Not propensity‐matched</p> <p>‐ The control group was a retrospectively‐matched cohort for baseline variables: "the treated and non‐treated patients were adequately matched for all the baseline variables" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection in the non‐PCC group and follow‐up coincided for all participants.</p> <p>PCCs all given in the OR. FFP usage similar between the two groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that PCC group participants were able to receive FFP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protocol for use of Confidex mentioned in methods</p> <p>Protocol stated how/when they received the standard treatment (FFP and cryo) vs PCCs.</p> <p>Used a clinically appropriate dose of PCC 25 u/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No mention of missing data</p> <p>‐ Prospective enrolment of the PCC group and data on excel spreadsheet. ‐ Unclear how they retrospectively obtained data for the control group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daily echo monitoring performed on all enrolled patients to exclude intracardiac thrombi. They did not do this for the retrospective control group. </p> <p> </p> <p>Not comparable assessment. Unclear if this resulted in significant differences because the PCC group had no incidence of intracardiac thrombi </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Due to serious bias in confounding</p> <p> </p> <p>‐ Small sample size (14 patients in PCC group vs. 11 patients in control group)</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Matching occurred with a control based on demographic and surgical characteristics;</p> <p>6/65 patients could not be matched</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>All PCCs and their 1:1:1 blood products given in OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined intervention group and comparison group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unclear dose of protamine/antifibrinolytics</p> <p>‐ If bleeding they used a 1:1:1: transfusion as per protocol</p> <p>‐ Intervention used if ongoing bleeding despite transfusion; this was based on clinician judgement </p> <p>‐ Control group got standard therapy, intervention group got PCCs if they continued to bleed (potentially a higher‐risk population) </p> <p>‐ Unclear if they used POC testing or lab bloods</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Collection of data ‐ retrospective data base analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective, assessors aware of intervention group</p> <p>‐ Objective outcomes</p> <p>Thromboembolic events were analysed for clinical signs of acute thrombosis in the medical charts and confirmed by radiographic evidence </p> <p>‐ Database analysis</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matched</p> <p> </p> <p>‐ No cross‐over occurred.</p> <p> </p> <p>‐ 18 patients unmatched (25%) from the PCC group because of more complex surgical procedure </p> <p> </p> <p>‐ Clear selection bias in choosing which patients received PCCs making it impossible to ascertain whether the complications observed were truly from the PCCs or the surgical complexity </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or clotting factor based therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unsure when intervention was given</p> <p>No mention of POC or lab tests</p> <p>No protocol</p> <p>The decision to give PCC was left up to the surgeon, anaesthetist, or intensivist</p> <p>Normal standard dose of PCC was 1500 units </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No reports of missing data.</p> <p> </p> <p>Collection of data ‐ from Austin hospital blood bank and cross‐referenced with the Australian Society of Cardiothoracic Surgeons database </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No mention of how they diagnosed thrombosis in patients</p> <p>‐ Clinical or radiological assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on absolute numbers and on matched pairs</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>CPB: Cardiopulmonary Bypass <br/>DVT: Deep Vein Thrombosis<br/>e‐CABG: electronic Coronary Artery Bypass Graft <br/>FFP: Fresh Frozen Plasma <br/>ICU: Intensive Care Unit <br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>PE: Pulmonary Embolism<br/>POC: Point Of Care <br/>rFVIIa: Recombinant Factor VIIa<br/>SMD: Standardised Mean Difference <br/>TXA: Tranexamic Acid <br/>vs: Versus </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for thrombotic events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for mortality</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0001" title="ArachchillageDJ , DeplanoS , DunnettE , OwenS , TillyerL , LaffanM . Efficacy and safety of prothrombin complex concentrate in patients undergoing major cardiac surgery. Blood2016;128(22):6. ">Arachchillage 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No matching occurred</p> <p> </p> <p>‐ The PCC group had higher‐complexity surgery, duration and individual participant risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups are clearly defined. The groups received either PCC or FFP.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No mention of dose given</p> <p>‐ No mention of co‐interventions</p> <p>‐ No mention of usual clinical practice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assumed this was low because the authors have not mentioned any missing data. No mention on how authors collected their data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No multiple subgroup analysis. Reported on what their methods stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>No matching of groups</p> <p>PCC patients were of a higher‐risk group.</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0004" title="BiancariF , RuggieriVG , PerrottiA , GherliR , DemalT , FranzeseI , et al. Comparative analysis of prothrombin complex concentrate and fresh frozen plasma in coronary surgery. Heart, Lung and Circulation2019;28(12):1881-7. ">Biancari 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ The intention of study was to review PCC vs FFP in patients undergoing cardiac surgery on CPB but they have included off‐CPB patients (FFP group 27% and PCC group 24%) </p> <p>‐ Propensity matching occurred (101 patients each group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC +/‐ FFP or FFP alone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised heparin, protamine and TXA protocol</p> <p>‐ Clinically appropriate dose of PCC and FFP</p> <p>‐ No agreed coagulation algorithm amongst the hospitals</p> <p>‐ There was no decision‐making process around when to give intervention or comparison.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Three patients had missing data on location of surgical bleeding</p> <p>‐ Collected data from e‐CABG registry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No multiple subgroup analysis. Reported on what their methods stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity matching</p> <p>‐ Important domains were measured and accounted for</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coinciding for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ This was not a deviation from standard practice.</p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Use of extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two types of analyses were conducted.</p> <p>‐ Propensity score‐adjusted  and propensity score‐matched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ There was matching of patients in each intervention group.</p> <p>‐ 69 patients in PCC group could not be matched due to being a higher‐risk population (emergency surgery, longer CPB time and complex surgery) </p> <p>‐ Two variables were not able to be matched with a SMD &lt; 10% (CPB time and diabetes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs all given intraoperatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that PCC group were able to receive FFP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised care mentioned</p> <p>‐ Both groups received rFVIIa with no statistical significance between the groups.</p> <p>‐ POC testing and lab tests to guide transfusion requirements</p> <p>‐ PCCs were given according to a protocol.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 18 patients excluded due to missing data (8%)</p> <p>‐ Data was obtained from institutional databases.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 patients of higher complexity were not included in the study. We believe these patients would have provided objective evidence for the higher‐risk population group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0011" title="HarrisAD , HubbardRM , SamRM , ZhangX , SalazarJ , GautamNK . A retrospective analysis of the use of 3-factor prothrombin complex concentrates for refractory bleeding after cardiopulmonary bypass in children undergoing heart surgery: a matched case-control study. Seminars in Cardiothoracic and Vascular Anaesthesia2020;24(3):227-31. ">Harris 2020a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Matching occurred with a control based on demographic and surgical characteristics.</p> <p>‐ 6/65 patients could not be matched.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>All PCCs and their 1:1:1 blood products given in OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined intervention group and comparison group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unclear dose of protamine/antifibrinolytics</p> <p>‐ If bleeding, they used a 1: 1:1: transfusion as per protocol.</p> <p>‐ Intervention used if ongoing bleeding despite transfusion; this was based on clinician judgement </p> <p>‐ Control group got standard therapy; intervention group got PCCs if they continued to bleed (potentially a higher‐risk population) </p> <p>‐ Unclear if they used POC testing or lab bloods</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Collection of data ‐ retrospective data base analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0018" title="ZwengI , GalvinS , RobbinsR , BellomoR , HartGK , SeevanayagamS , et al. Initial experience of the use of 3-factor prothrombin complex concentrate and thromboembolic complications after cardiac surgery. Heart, Lung and Circulation2019;28(11):1706-13. ">Zweng 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matched</p> <p> </p> <p>‐ No cross‐over occurred.</p> <p> </p> <p>‐ 18 patients unmatched (25%) from the PCC group because of more complex surgical procedure </p> <p> </p> <p>‐ Clear selection bias in choosing which patients received PCCs making it impossible to ascertain whether the complications observed were truly from the PCCs or the surgical complexity. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or clotting factor‐based therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unsure when intervention ws given.</p> <p>No mention of POC or lab tests</p> <p>No protocol</p> <p>The decision to give PCC was left up to the surgeon, anaesthetist, or intensivist.</p> <p>Normal standard dose of PCC was 1500 units </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No reports of missing data.</p> <p> </p> <p>Collection of data ‐ from Austin hospital blood bank and cross‐referenced with the Australian Society of Cardiothoracic Surgeons database </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on absolute numbers and matched pairs </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>CPB: Cardiopulmonary Bypass <br/>e‐CABG: electronic Coronary Artery Bypass Graft<br/>FFP: Fresh Frozen Plasma <br/>ICU: Intensive Care Unit <br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>POC: Point Of Care <br/>rFVIIa: Recombinant Factor VIIa<br/>SMD: Standardised Mean Difference <br/>TXA: Tranexamic Acid  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for ICU length of stay</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity matching</p> <p>‐ Important domains were measured and accounted for</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Use of extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two types of analysis:</p> <p>Propensity score‐adjusted and propensity score‐matched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>FFP: Fresh Frozen Plasma<br/>PCC: Prothrombin Complex Concentrate </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for ICU length of stay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for renal replacement therapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity matching</p> <p>‐ Important domains were measured and accounted for</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ This was not a deviation from standard practice.</p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Use of extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two types of analysis: propensity score‐adjusted and propensity score‐matched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0006" title="FitzgeraldJ , LenihanM , CallumJ , McCluskeySA , SrinivasC , Van RensburgA , et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. British Journal of Anaesthesia2018;120(5):928-34. LenihanM , FitzgeraldJ , CallumJ , McCluskeyS , SrinivasC , KarkoutiK . Use of prothrombin complex concentrate versus frozen plasma for bleeding after cardiac surgery. Canadian Journal of Anaesthesia2018;65(Suppl 1):S15-S16. ">Fitzgerald 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ There was matching for patients in each intervention group.</p> <p>‐ 69 patients in PCC group could not be matched due to being a higher‐risk population (emergency surgery, longer CPB time and complex surgery). </p> <p>‐ Two variables were not able to be matched with a SMD &lt;10% (CPB time and diabetes).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>PCCs all given intraoperatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that PCC group were able to receive FFP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Standardised care mentioned</p> <p>‐ Both groups received rFVIIa with no statistical significance between the groups.</p> <p>‐ POC testing and lab tests to guide transfusion requirements</p> <p>‐ PCCs were given according to a protocol.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 18 patients excluded due to missing data (8%)</p> <p>‐ Data were obtained from institutional databases.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 69 patients of higher complexity were not included in the study. These patients would have provided objective evidence for the higher‐risk population group. </p> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>CPB: Cardiopulmonary Bypass<br/>PCC: Prothombin Complex Concentrate<br/>POC: Point of Care Testing<br/>rFVIIa: Recombinant Factor VIIa<br/>SMD: Standardisd Mean Difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for renal replacement therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for ventilator hours</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0005" title="CappabiancaG , MariscalcoG , BiancariF , MaselliD , PapessoF , CottiniM , et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Critical Care2016;20:5. ">Cappabianca 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Attempted to control with propensity matching</p> <p>‐ Important domains were measured and accounted for.</p> <p>‐ Propensity one‐to‐one score and propensity score‐adjusted multivariate analysis was used (what score used changed AKI results) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coinciding for all participants.</p> <p>PCCs were all given intraoperatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or FFP alone. They did not mention a PCC + FFP group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ This was not a deviation from standard practice.</p> <p> </p> <p>‐ This was not defined in their methods for analysing the two groups.</p> <p> </p> <p>‐ Product usage was guided by POC testing, blood labs.</p> <p> </p> <p>‐ Use of extra products was at the discretion of the treating clinician.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Data were prospectively collected and recorded in computerised database registries that remained consistent during the study period. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p>Propensity score‐adjusted and propensity score‐matched pairs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AKI: Acute Kidney Injury<br/>FFP: Fresh Frozen Plasma<br/>PCC: Prothrombin Complex Concentrate<br/>POC: Point of Care </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">ROBINS‐I PCC versus standard treatment; assessments for ventilator hours</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for blood products (RBC) transfused</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matching occurred for all baseline characteristics except EGFR and procedure type. </p> <p> </p> <p>‐ Procedure type appeared to be more complex in the PCC group.</p> <p> </p> <p>‐ 5 of the remaining 58 were then excluded due to inability to be matched with rFVIIa group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>Both PCCs and FVIIa were given in OR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that they analysed patients receiving PCCs or rFVIIa. No definition of what constituted refractory bleeding and initiation of interventions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ rFVIIa group received 90 mcg/kg and PCC group received 27 IU/kg (median).</p> <p> </p> <p>‐ The rFVIIa dose exceeded recognised and accepted doses for rFVIIa.</p> <p>‐ No definition of when patients received intervention</p> <p>‐ This was a safety study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 14/72 patients had incomplete data therefore were excluded.</p> <p> </p> <p>Data were collected via an electronic medical record database that was retrospectively queried. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as described in their methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> High rFVIIa dose exceeding common recommended practice</p> <p> </p> <p>‐ Uncertainty around increased cell salvage and product administration in the rFVIIa group. This could be result of clinician bias or a higher risk population. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Matched on age, sex and CPB duration</p> <p> </p> <p>‐ Other factors unmatched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 40% of patients received rFVIIa in ICU.</p> <p>‐ 100% of patients received PCCs in theatre.</p> <p>Follow‐up may have started before intervention.</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Followed institutional protocol</p> <p> </p> <p>‐ Cross‐over of patients in PCC group (24% patients in the PCC group also received rVIIa). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data</p> <p> </p> <p>Collection of data not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group.</p> <p>‐ Objective outcomes</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Editorial, not a published paper</p> <p> </p> <p>‐ Comparable doses</p> <p> </p> <p>‐ Not propensity matched</p> <p> </p> <p>‐ Issues with initiation of intervention (theatre vs ICU)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>CPB: Cardiopulmonary Bypass<br/>EGFR: Estimated Glomerular Filtration Rate<br/>ICU: Intensive Care Unit<br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>rFVIIa: Recombinant Factor VIIa </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for blood products (RBC) transfused</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0010"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for thrombotic events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Only 22 patients</p> <p>‐ No matching occurred</p> <p>‐ Patients received either PCC or rFVIIa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or rFVIIa.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unclear decision‐making process of clinicians treating patients with intervention</p> <p>No mention of POC or Lab tests</p> <p>‐ No mention of use of tranexamic acid and protamine</p> <p>‐ Increased FFP usage in the PCC group</p> <p>‐ Mild dose of rFVIIa (32 mcg/kg) compared with PCC (20 IU/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data. Chart review from paper and electronic documentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group.</p> <p>‐ Did not mention how they detected thrombosis and thrombotic events (i.e. clinically or radiological assessment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on what their methods stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>‐ No matching </p> <p>‐ Small sample size </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matching occurred for all baseline characteristics except EGFR and procedure type. </p> <p> </p> <p>‐ Procedure type appeared to be more complex in the PCC group.</p> <p> </p> <p>‐ 5 of the remaining 58 were then excluded due to inability to be matched with rFVIIa group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>Both PCCs and FVIIa were given in OR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that they analysed patients receiving PCCs or rFVIIa. No definition of what constituted refractory bleeding and initiation of interventions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ rFVIIa group received 90mcg/kg and PCC group received 27 IU/kg (median).</p> <p> </p> <p>‐ The rFVIIa dose exceeded recognised and accepted doses for rFVIIa.</p> <p>‐ No definition of when patients received intervention</p> <p>‐ This was a safety study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 14/72 patients had incomplete data therefore were excluded.</p> <p> </p> <p>Data were collected via an electronic medical record database that was retrospectively queried. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ CVA defined as new postoperative stroke being documented by a neurologist in the electronic medical record or on autopsy </p> <p>‐ DVT defined as postoperative ultrasound diagnosing acute DVT</p> <p>‐ PE defined as CT or autopsy demonstrating acute PE</p> <p>‐ MI defined as new native coronary artery or coronary artery bypass graft occlusion demonstrated on postoperative cardiac catheterisation or wall motion abnormalities seen on echocardiogram that resolved with PCI or CABG </p> <p>‐ All new intracardiac thrombus as noted on postoperative echo or autopsy </p> <p>Electronic medical record retrospectively queried</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High rFVIIa dose exceeding common recommended practice</p> <p> </p> <p>Matched for most of baseline variables</p> <p> </p> <p>‐ Uncertainty around increased cell salvage and product administration in the rFVIIa group. This could be result of clinician bias or a higher‐risk population. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0015" title="MehringerSL , KlickZ , BainJ , McNeelyEB , SubramanianS , PassLJ , et al. Activated factor 7 versus 4-factor prothrombin complex concentrate for critical bleeding post-cardiac surgery. Annals of Pharmacotherapy2018;52(6):533-7. ">Mehringer 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No propensity matching occurred.</p> <p> </p> <p>‐ Two groups had baseline differences in haemoglobin concentration and haematocrit.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> <p>Unclear in the study when given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or rFVIIa alone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ No mention of coagulation studies or coagulation algorithm</p> <p>‐ Decision to give intervention was based on clinical judgement.</p> <p>‐ High rFVIIa dose</p> <p>‐ Intervention not comparable due to differences in doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data</p> <p> </p> <p>Collection of data ‐ electronic health record system</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group.</p> <p>‐ No mention of how they diagnosed thrombosis in patients: clinical or radiological assessment </p> <p> </p> <p>Collected data from electronic medical record system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Not matched</p> <p> </p> <p>‐ High dose of rFVIIa dose (decided by surgeons) that was higher than most institutions standard practice ‐ 66 mcg/kg </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Matched on age, sex and CPB duration</p> <p> </p> <p>‐ Other factors unmatched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 40% of patients received rFVIIa in ICU.</p> <p>‐ 100% of patients received PCCs in theatre.</p> <p>‐ Follow‐up may have started before intervention.</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Followed institutional protocol</p> <p> </p> <p>‐ Cross‐over of patients in PCC group (24% patients in the PCC group also received rVIIa). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data</p> <p> </p> <p>Collection of data not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Retrospective; assessors aware of intervention group.</p> <p> </p> <p>No mention of how they diagnosed thrombosis in patients: clinical or radiological assessment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>‐ Comparable doses</p> <p> </p> <p>‐ Not matched</p> <p> </p> <p>‐ Issues with initiation of intervention (theatre vs ICU)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>CABG: Coronary Artery Bypass Graft Surgery<br/>CPB: Cardiopulmonary Bypass<br/>CT: Computed Tomography<br/>CVA: Cerebrovascular Accident<br/>DVT: Deept Vein Thrombosis<br/>EGFR: Estimated Glomerular Filtration Rate<br/>FFP: Fresh Frozen Plasma<br/>ICU: Intensive Care Unit<br/>MI: Myocardial Infarction<br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>PCI: Percutaneous Coronary Intervention<br/>PE: Pulmonary Embolism<br/>POC: Point Of Care <br/>rFVIIa: Recombinant Factor VIIa </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for thrombotic events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0011"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for mortality</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0003" title="AudleyK , RosiniJ , TullyA , ZizzaL . Use of four-factor prothrombin complex concentrate versus activated factor seven in cardiac surgery. Critical Care Medicine2019;47:1. ">Audley 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Only 22 patients</p> <p>‐ No matching occurred.</p> <p>‐ Patients received either PCC or rFVIIa.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown whether PCCs given in OR or ICU; follow‐up may have started before intervention.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined. The groups received either PCC or rFVIIa.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Unclear decision‐making process of clinicians treating patients with intervention</p> <p>No mention of POC or Lab tests</p> <p>‐ No mention of use of tranexamic acid and protamine</p> <p>‐ Increased FFP usage in the PCC group</p> <p>‐ Mild dose of rFVIIa (32 mcg/kg) compared with PCC (20 IU/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data</p> <p>Chart review from paper and electronic documentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on what their methods stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>‐ No matching of groups</p> <p> </p> <p>‐ Small sample size may have contributed to analysing outcomes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matching occurred for all baseline characteristics except EGFR and procedure type. </p> <p> </p> <p>‐ Procedure type appeared to be more complex in the PCC group.</p> <p> </p> <p>‐ 5 of the remaining 58 were then excluded due to inability to be matched with rFVIIa group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coinciding for all participants.</p> <p>Both PCCs and FVIIa were given in OR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that they analysed patients receiving PCCs or rFVIIa. No definition of what constituted refractory bleeding and initiation of interventions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ rFVIIa group received 90 mcg/kg and PCC group received 27 IU/kg (median).</p> <p> </p> <p>‐ The rFVIIa dose exceeded recognised and accepted doses for rFVIIa.</p> <p>‐ No definition of when patients received intervention</p> <p>‐ This was a safety study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 14/72 patients had incomplete data, therefore were excluded.</p> <p> </p> <p>Data were collected via an electronic medical record database that was retrospectively queried. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High rFVIIa dose exceeding common recommended practice</p> <p> </p> <p>Matched for most of baseline variables </p> <p> </p> <p>Uncertainty around increased cell salvage and product administration in the rFVIIa group This could be a higher‐risk population. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0017" title="TanakaKA , MazzeffiMA , GrubeM , OgawaS , ChenEP . Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion2013;53(4):920-1. ">Tanaka 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Critical risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Matched on age, sex and CPB duration</p> <p> </p> <p>‐ Other factors unmatched</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 40% of patients received rFVIIa in ICU.</p> <p>‐ 100% of patients received PCCs in theatre.</p> <p>Follow‐up may have started before intervention.</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention groups were clearly defined.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Followed institutional protocol</p> <p> </p> <p>‐ Cross‐over of patients in PCC group (24% patients in the PCC group also received rVIIa). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No mention of missing data</p> <p> </p> <p>Collection of data not mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective; assessors aware of intervention group.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> <p> </p> <p>Comparable doses</p> <p> </p> <p>Not matched</p> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>CPB: Cardiopulmonary Bypass<br/>EGFR: Estimated Glomerular Filtration Rate<br/>FFP: Fresh Frozen Plasma<br/>ICU: Intensive Care Unit<br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>POC: Point Of Care<br/>rFVIIa: Recombinant Factor VIIa </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0012"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for ICU length of stay</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matching occurred for all baseline characteristics except EGFR and procedure type </p> <p> </p> <p>‐ Procedure type appeared to be more complex in the PCC group</p> <p> </p> <p>‐ 5 of the remaining 58 were then excluded due to inability to be matched with rFVIIa group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coincided for all participants.</p> <p>Both PCCs and FVIIa were given in OR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that they analysed patients receiving PCCs or rFVIIa. No definition of what constituted refractory bleeding and initiation of interventions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ rFVIIa group received 90 mcg/kg and PCC group received 27 IU/kg (median).</p> <p> </p> <p>‐ The rFVIIa dose exceeded recognised and accepted doses for rFVIIa.</p> <p>‐ No definition of when patients received intervention</p> <p>‐ This was a safety study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 14/72 patients had incomplete data, therefore were excluded.</p> <p> </p> <p>Data were collected via an electronic medical record database that was retrospectively queried. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High rFVIIa dose exceeding common recommended practice</p> <p> </p> <p>Matched for most of baseline variables </p> <p> </p> <p>Increased cell salvage and product administration in the rFVIIa group This could be a higher‐risk population. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>EGFR: Estimated Glomerular Filtration Rate<br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>rFVIIa: Recombinant Factor VIIa </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; assessments for ICU length of stay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013551-tbl-0013"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; renal replacement therapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to confounding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of participants into the study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in classification of interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to deviations from the intended intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias due to missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in measurement of outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias in selection of the reported result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013551-bbs2-0010" title="HarperPC , SmithMM , BrinkmanNJ , PasseMA , SchroederDR , SaidSM , et al. Outcomes following three-factor inactive prothrombin complex concentrate versus recombinant activated Factor VII administration during cardiac surgery. Journal of Cardiothoracic and Vascular Anaesthesia2018;32(1):151-7. ">Harper 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Low risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious risk</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ Propensity matching occurred for all baseline characteristics except EGFR and procedure type. </p> <p> </p> <p>‐ Procedure type appeared to be more complex in the PCC group.</p> <p> </p> <p>‐ 5 of the remaining 58 were then excluded due to inability to be matched with rFVIIa group. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective collection with intervention and follow‐up coinciding for all participants.</p> <p>Both PCCs and FVIIa were given in OR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Defined two groups from the beginning and stated that they analysed patients receiving PCCs or rFVIIa. No definition of what constituted refractory bleeding and initiation of interventions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ rFVIIa group received 90 mcg/kg and PCC group received 27 IU/kg (median).</p> <p> </p> <p>‐ The rFVIIa dose exceeded recognised and accepted doses for rFVIIa.</p> <p>‐ No definition of when patients received intervention</p> <p>‐ This was a safety study.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 14/72 patients had incomplete data, therefore were excluded.</p> <p> </p> <p>Data was collected via an electronic medical record database that was retrospectively queried. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported on all outcome measures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ High rFVIIa dose exceeding common recommended practice</p> <p> </p> <p>‐ Authors matched for most of baseline variables </p> <p> </p> <p>Increased cell salvage and product administration in the rFVIIa group </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>EGFR: Estimated Glomerular Filtration Rate<br/>OR: Operating Room<br/>PCC: Prothrombin Complex Concentrate<br/>rFVIIa: Recombinant Factor VIIa </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">ROBINS‐I PCC versus rFVIIa; renal replacement therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/full#CD013551-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013551-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PCC versus standard treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 RCT: Blood products transfused (RBC) in units <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐1.78, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 NRS: Blood products transfused (RBC) in units <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.87 [‐2.53, ‐1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 RCT: Blood products transfused (RBC) % of patients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.20, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 NRS: Blood products transfused (RBC) % of patients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.30, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 RCT: Thrombotic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.20, 2.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 NRS: Thrombotic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.87, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 NRS: Thrombotic events matched data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.87, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Matched data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.87, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 NRS: Thrombotic events (3‐factor vs 4‐factor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.84, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 3‐factor PCCs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.88, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 4‐factor PCCs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.33, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 RCT: Mortality (30‐day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.12, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 NRS: Mortality (30‐day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.69, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 NRS: Mortality (30‐day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.68, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Matched data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.68, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 RCT: Bleeding (chest drain output) in mLs for the first 12 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐107.05 [‐278.92, 64.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 RCT: Intensive care length of stay in hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐19.26, 18.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 NRS: Intensive care length of stay in hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.00 [‐43.14, 7.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 RCT: Incidence of renal replacement therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.14, 3.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 NRS: Incidence of renal replacement therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.71, 2.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 RCT: Ventilator hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐4.49, 2.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 NRS: Ventilator hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.20 [‐23.10, 12.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PCC versus standard treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013551-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">PCC versus rFVIIa</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Blood products transfused (RBC) in units <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Intraoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.98 [‐6.37, ‐3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Postoperative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.06 [‐2.48, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Blood products transfused (RBC) % of patients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.02, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Thrombotic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.23, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Mortality (30‐day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.38, 3.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Bleeding (chest drain output) in mLs for the first 12 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐674.34 [‐906.04, ‐442.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Intensive care length of stay in hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐40.00 [‐110.41, 30.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Incidence of renal replacement therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">PCC versus rFVIIa</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013551.pub2/references#CD013551-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013551.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013551-note-0023">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013551-note-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013551-note-0022">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013551-note-0020">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013551-note-0019">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013551-note-0017">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013551-note-0018">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013551-note-0016">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013551\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013551\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013551\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013551\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013551\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013551.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013551.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013551.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013551.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013551.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725955118"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013551.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725955122"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013551.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e87d868a59371',t:'MTc0MDcyNTk1NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 